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1. Introduction
1.1 Anatomy of the Pancreas
1.1.1 Gross Anatomy of the Pancreas
The pancreas (from the Greek meaning ‘all flesh’) is a retroperitoneal organ located posterior to 
the stomach on the posterior abdominal wall. Macroscopically, the pancreas in humans is a 
small elongated well-defined organ of compact structure, whereas in rodents it is distributed 
between different parts of the intestines and the spleen and not easily distinguishable from the 
surrounding adipose tissue. The pancreas develops from the innermost of the 3 germ layers 
called the endoderm. After the gut tube has formed in the embryo, several buds grow below the 
section that widens to become the stomach. These buds extend and branch to generate the liver, 
the gallbladder, and the pancreas rudiments (Spooner et al., 1970). Differential rotation and 
fusion of the ventral and dorsal pancreatic buds results in the formation of the definitive 
pancreas. The dorsal pancreatic bud gives rise to the anterior part of the head of the pancreas, in 
addition to the body and tail, while the ventral pancreatic bud develops into the posterior part of 
the pancreatic head (Slack, 1995). Fusion of the pancreatic buds is accompanied by anastomosis 
of the ducts. The main drainage duct of the ventral pancreatic bud communicates with the main 
duct of the dorsal pancreatic bud, with the point of union lying between the isthmus and head of 
the pancreas. This becomes the dominant and more constant pancreatic duct; duct of Wirsung 
(Kamisawa, 2004). The cells of the branching pancreatic buds differentiate according to their 
functions. The cells at the end of the branches form a cap of acinar (Latin: berry) cells, 
producing digestive juice. The cells lining the branches become ductal cell, transporting the 
products of the acinar cells to the intestine. By time, a special group of cells detaches from the 
branches and assembles into small colonies called pancreatic islets. These cells will eventually 
become the signaling centers of the pancreas (Collombat et al., 2006).
1.1.2 Microscopic Anatomy
The normal adult human pancreas is composed of exocrine tissue (80 % of the total mass), 
ducts, vessels, nerves, and connective tissue (18 % of the total mass) and endocrine tissue (2 %); 
about 1 million islets. Islets of Langerhans, named after their discoverer Paul Langerhans, 
constitute a unique endocrine organ consisting of insulin-??????????? cells (65-80 % of the total 
islet cell population), glucagon-??????????? cells (15-20 %), somatostatin-??????????? cells (3-
10 %), ghrelin-producing ?-cells, and pancreatic polypeptide (PP) cells (Rahier et al., 1981). 
Across species, there are major differences in islet structure, distribution of islets into particular 
parts of the gland, and regional variations in the numbers of specific islet cells. In rodent islets, 
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???????????????????????????????????????????????????????????????????????????ound islet, surrounded 
??????????????????????????????????????????????????????????While some studies suggest that the tail 
(or splenic part) of the pancreas contains the highest concentration of islets (Elayat et al., 1995), 
others had found that islet size and distribution are similar in different regions of the adult 
mouse pancreas (Kim et al., 2009). On the other hand, the human islets lack the typical core–
mantle architecture of rodent islets and ?? ?????? ???? ???????? ??? ??????? ????-like clusters 
intermingled with the other kinds of endocrine cells (Brissova et al., 2005). Islet cells may 
interact with each other through direct contact and through systemic or paracrine effects. The 
highly specialized pattern of blood flow through the islet probably controls local and systemic 
interactions. Although the islets constitute only a minor part of the total pancreatic mass (1 %), 
they receive about 15-20 % of total pancreatic blood flow and this portion is further increased 
when glucose level is increased (Ballian and Brunicardi, 2007; Nyman et al., 2010). This effect 
is thought to be mediated by interactions between the parasympathetic nervous system and 
locally produced metabolites, mainly adenosine (Carlsson et al., 2002). However, Jansson et al.
(2008) reported that increased insulin secretion in response to increased glucose concentration 
was without concomitant increase in islet blood flow. The effects of anti-diabetic agents on islet 
blood flow were investigated in a few studies using the microsphere technique in anesthetized 
rats. However, conflicting results were reported for sulfonylureas, e.g., tolbutamide increased 
islet blood flow (Vetterlein et al., 1985), whereas glipizide decreased it (Jansson et al., 2003).
??? ???? ?????? ?????? ?? ????????? ????????? ?????r to suppress the hyperglycemia-induced islet 
hyperperfusion, which may ameliorate hemodynamic stress in pancreatic islets (Iwase et al., 
2009).
1.1.3 ????? cell
????? cell is the most abundant cell type in the islet of Langerhans and solely builds up its core. 
??????????????????????????????? cells can be discriminated morphologically from other types by 
their ellipsoid shape and bigger size. Furthermore, different electrophysiological properties also 
??????????????????????? ???????????????? cells (Gopel et al., 1999).  The different cell types of the 
pancreatic islets are regulated by complex para- and autocrine interactions that are yet not fully 
??????????? ??? ?????????????????????? ???? ??????????? ????????????????? ??????????????????????? cells 
????? ?? ????????????? ????? ?????????? ????? ???? ???????? ?? ????????? ??? ????? ?????? ????????? ??? ?????
2003; Ravier ??????????????????????????????????????????????????????????????????????????????????????
????????? ???????? ????? ?? ?????? ??????????? ????? ???????? ???????? ??? ????? ???5) and somatostatin 
???????? ??? ????? ?????? ??????????? ???? ???????? ??? ?????? ???????????? ????????? ????? ?? ???? ?? ?????
(Strowski et al., 2003). Proinsulin, the precursor of insulin, is synthesized in the endoplasmic 
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reticulum and undergoes a series of maturation steps, starting already in the Golgi. The product 
is then packaged into secretory granules that gradually acidify, allowing further processing to 
insulin (Hutton, 1994). The resulting insulin has a lower solubility and so it co-precipitates with 
zinc ions to form microcrystals within the secretory granule (Orci et al., 1986).  
1.2 Physiology of the Pancreas
1.2.1 Stimulus-secretion coupling 
The term "stimulus secretion coupling" in the endocrine cells was developed by Douglas and 
Rubin (1963). It is now being widely accepted, that stimulus secretion coupling in ? cells is 
achieved by at least two interconnected pathways for which the two terms "KATP channel 
dependent" or "triggering" pathway and ‘KATP channel-independent’ or "amplifying" pathway 
are in common use today (Henquin, 2000). 
1.2.1.1 The triggering pathway
ATP-sensitive K+ (KATP) channels are key players in the triggering pathway (Henquin, 2000). 
The ? cell KATP channel is a hetero-octameric complex formed from four inwardly rectifying 
potassium channel subunits (termed Kir6.2) and four sulphonylurea receptor subunits (SUR1). 
Both subunits are required to form a functional channel. The Kir6.2 subunits build up the 
channel pore through which potassium ions flow. The name of Kir came from the fact that these 
channels conduct K+ current into the cell more easily than to the outside of the cell (reviewed in 
Hibino et al., 2010). SUR1 subunits surround the Kir6.2 subunits, is expressed at high levels in 
pancreatic islets and pancreatic ? cell lines including MIN6 and RINm5F (Inagaki et al., 1995a). 
The activity of KATP channels is modulated by changes in the ATP/ADP ratio. SUR1 mediates 
the opening action of Mg2+-ADP (Gribble et al., 1998), whereas the closing action of ATP is on 
Kir6.2 itself. SUR1 subunit, as implied by its name, binds sulphonylurea, which close the 
channel, while it is activated by diazoxide (Bryan et al., 2004). At non stimulatory glucose 
concentrations, KATP channels have a high opening probability leading to a net outflow of K
+
ions through spontaneously active KATP channels. With the K
+ ????????????????????????????? cell 
membrane this results in a negative membrane potential of around -70 mV. An increase in the 
????????????????????????????????????????????????????????????????????????????????????????????????
by means of a high affinity membrane bound Glucose Transporter (GLUT1 in humans; GLUT2 
in rodents) (Scheepers et al., 2004; Thorens and Mueckler, 2010). Glucose is rapidly 
phosphorylated to glucose 6-phosphate by glucokinase, which thereafter acts as the glucose 
sensor of the ? cells. Subsequent oxidative metabolism provides pyruvate which is channelled 
into the mitochondria via Krebs cycle, resulting in the production of NADH and FADH2. The 
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resultant increase in the ATP/ADP ratio in the cytosol causes depolarization of the plasma 
membrane by closure of the KATP channels. This permits opening of voltage - dependent Ca
2+
channels (VDCC) accompanied by release of Ca2+ into cytosol and subsequently, Ca2+
dependent action potential firing is initiated. Native pancre????? ? cells and cell lines have 
different types of VDCC. These channels are classified according to their open probability in 
low-voltage-activated (LVA, type T channels) or high-voltage-activated (HVA, L, N, P/Q, and 
R). In both types, they all form hete???????????????????????????????????????????????? subunits. 
L-type Ca2+ channels are considered the most important Ca2+ entry pathway that controls insulin 
secretion in primary ? cells and cell lines (Yang and Berggren, 2006; Hiriart and Aguilar-Bryan, 
2008). It has been shown that the increase of ? cell calcium channel activity and / or density 
results in enhanced insulin exocytosis (Yang and Berggren, 2005). Moreover, these channels are 
also involved in ? cell development, survival, and growth (Namkung et al., 2001). The voltage 
gated K+ channels, are responsible for repolarization of the pancreatic ? cells (MacDonald et al., 
2001). The subsequent increase in cytosolic free Ca2+ coupled with the multiple phosphorylation 
events modulated by protein kinase C (PKC) and protein kinase A (PKA) induce exocytosis and 
insulin secretion (Ashcroft et al., 1994). This general model of glucose stimulated insulin 
secretion (GSIS) is widely accepted today especially because most experimental conditions that 
interfere with the rise in [Ca2+]i impair glucose-induced insulin secretion, whereas all agents, 
either physiological or pharmacological, that increase ?? ????? [Ca2+]i induce insulin secretion 
(Henquin, 2000 and 2004). However, if [Ca2+]i is accompanied by  a reduced ATP level, it is 
unlikely to elicit a secretory response (Rustenbeck et al., 1997a).
1.2.1.2 The amplifying pathway
While evidence supporting the essential role of KATP channels in glucose-induced insulin 
secretion was accumulating, the possibility that glucose had additional independent effects was 
expressed by investigators many years ago. One study showed that 15 mM glucose alone 
induced a higher rate of insulin secretion than a combination of 10 mM glucose and 5 ???
tolbutamide, although both conditions produced similar electrical activity and, presumably, a 
similar increase of [Ca2+]i in ? cells. It was therefore proposed that non-electrogenic effects of 
glucose amplify insulin secretion (Henquin, 1988). Another study reported that glucose was able 
to increase insulin secretion, in the presence of sulfonylurea concentrations sufficient to close all 
KATP channels leading to the proposal that glucose was acting on other targets (Panten et al., 
1988). Two independent studies (Gembal et al., 1992; Sato et al., 1992) had shown that glucose-
independently of KATP channels was still able to evoke an increase in insulin secretion above the 
already raised basal level in mouse or rat islets depolarized by KCl in the presence of diazoxide 
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i.e. when KATP channels were held open pharmacologically. This effect of glucose was shown to 
depend on metabolism, to require elevated [Ca2+]i (by KCl-induced depolarization in these 
experiments), but was not found to involve a further rise in [Ca2+]i (Gembal et al., 1992). 
Moreover, glucose was recently reported to increase insulin secretion from mouse islets lacking 
KATP channels which confirm amplification to the signaling mechanism that circumvents
depolarization–mediated effect (Nenquin et al., 2004; Ravier et al., 2009). Several approaches 
using intact or permeabilised cells have shown the involvement of ATP at steps of the secretory 
process distal to the [Ca2+]i rise (Detimary et al., 1994; Rustenbeck et al., 1997a). Recent studies 
call for a evaluation of the roles of citrate cycle intermediates exported to the cytosol via 
cataplerosis (MacDonald et al., 2005), cAMP (Dyachok et al., 2008), NAD(P)H (Ivarsson  et al., 
2005; Reinbothe et al., 2009), AMP-activated protein kinase (Rutter and Leclerc, 2009).
Figure 1.1 ?????? ???? ????????? ???????? ??????????? ??? ???????? ?????????? ??? ???? ?? ????. Glucose 
equilibrates across the plasma membrane and is phosphorylated by glucokinase (GK), which initiates its 
conversion to pyruvate (Pyr) by glycolysis. Pyr preferentially enters the mitochondria and fuels the TCA 
cycle, resulting in the transfer of reducing equivalents (red.equ.) to the respiratory chain, leading to 
hyperpolarization of the mitochondrial membrane (???) and generation of ATP. ATP is then transferred 
to the cytosol, raising the ATP/ADP ratio. Subsequently, closure of KATP channels depolarizes the cell 
membrane. This opens voltage-gated Ca2+ channels, increasing the cytosolic Ca2+ concentration (Ca2+)i, 
which triggers insulin exocytosis (Maechler, 2002).
1.2.2 Neuronal regulation of insulin release
Both parasympathetic and sympathetic nerves have an important effect on islet secretory 
activity. It is thought that feeding induces the parasympathetic nervous system (rest and digest 
mood), which facilitates insulin secretion in a glucose-dependent manner (Brunicardi et al., 
1995). Pancreatic ganglia are supposed to govern the synchronicity of insulin secretion between 
islets observed over the whole pancreas (Stagner and Samols, 1985). Furthermore, sympathetic 
activity (fight and flight mood) was reported to regulate the homeostasis of glucose by adjusting 
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insulin secretion to stressful conditions including exercise (Järhult and Holst, 1979). The islets 
are densely innervated by nerve fibers, which are closely related to blood vessels terminating 
close to islet cells (Burris and Hebrok, 2007). Studies on the islet innervating fibers with 
histochemical and fluorescence staining revealed not only nerves containing the classical 
neurotransmitter acetylcholine and norepinephrine (Coupland, 1958; Cegrell, 1968), but also a 
variety of established and putative neuropeptides (Boonen et al., 2007). Pancreatic islets are 
abundantly innervated by parasympathetic nerves (from the vagus nerve) releasing acetylcholine 
which enhance insulin secretion in different species (Ahrén, 2000; Gilon and Henquin, 2001). 
Among the five different muscarinic receptors, only the M3 in mice was found to be important 
for the cholinergic stimulation of glucagon and insulin secretion (Duttaroy et al., 2004; Gautam
et al., 2008). Catecholamines have a dual effect on the ? cell to induce either inhibition or 
stimulation of insulin secretion through their interaction with ?2 or ?1 and ?2 adrenergic 
receptors, respectively (Skoglund et al., 1986; Savontaus et al., 2008). Apart from 
parasympathetic and sympathetic nerves, several other fibers innervate the islets although their 
contributions to control islet hormone secretion are unclear. Neuropeptides were discovered in 
nerve terminals in pancreatic ganglia and in islets in several species: vasoactive intestinal 
polypeptide (VIP), gastrin releasing peptide (GRP) and pituitary adenylate cyclase activating 
polypeptide (PACAP). These neuropeptides are released from the pancreas on electrical 
stimulation of the vagus and stimulate both insulin and glucagon secretion (Fridolf et al., 1992;
Winzell and Ahrén, 2007). Other neuropeptides including calcitonin-gene related peptide 
(CGRP) and substance P are thought to be involved in the synthesis and/or release of insulin 
from secretory granules (Edwin and Leigh, 1999; Adeghate and Ponery, 2003). 
1.3 Fluoroquinolone antibiotics 
1.3.1 History and Classification
Quinolones are widely used antimicrobial agents. The development of these drugs started with 
the non-fluorinated drug nalidixic acid in the early 1960s and proceeded in the 1980s to the first 
6-fluorinated derivatives with enhanced activity against Gram-negative bacteria (e.g. 
norfloxacin, ofloxacin, ciprofloxacin). At that time, it was generally believed that fluorination is 
essential to obtain drugs with high anti-bacterial activity. Later on, fluoroquinolones with 
improved activity against Gram-positive bacteria (e.g. moxifloxacin, gatifloxacin) have come to 
therapeutic use. Recently, highly active quinolones have been developed which are not 
fluorinated in position 6, but bear fluorine atoms at the side chain (e.g. BMS-284756) or are 
non-fluorinated derivatives (e.g. PGE 9509924). Thus, some prefer to avoid the term 
fluoroquinolones and rather call them more generally ‘quinolones’, although they differ 
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considerably from the classic drugs such as nalidixic acid. With the given multiplicity of 
quinolones, it is necessary to group them according to their features in different classes as has 
been proposed by the Paul–Ehrlich-Society of Chemotherapy (PEC). Those fluoroquinolones 
that are most often used today for the treatment of bacterial infections, mainly urinary tract 
infections and respiratory tract infections, and that are considered relatively safe and well-
tolerated drugs are compiled in Table 1.1 (Naber and Adam, 1998; Stahlmann, 2002). Compared 
to other antibiotics, fluoroquinolones have rapid bactericidal effect with good oral absorption, 
prolonged half-lives, and efficacy, concentrated in tissues at levels that often exceed their serum 
concentrations. They exert their bactericidal effect by interfering with DNA topoisomerase II 
and IV (Mitscher, 2005).
Table 1.1 Widely used fluoroquinolones grouped according to the PEC classification 
Class Fluoroquinolone Spectrum / therapeutic use
I Norfloxacin Mainly active against Gram negative pathogens, almost 
exclusively used for urinary tract infections
II Ofloxacin  and 
Ciprofloxacin
Broad indications for systemic use, but moderate activity against 
Gram positive pathogens
III Levofloxacin Improved activity against  Gram positive and atypical pathogens, 
infections of the respiratory tract and others
IV Moxifloxacin and 
Gatifloxacin 
Improved activity against  Gram positive and atypical pathogens 
as well as anaerobes, infections of the respiratory tract and others
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1.3.2 Special uses
Generally, fluoroquinolone use for children has been avoided, except in circumstances where 
alternative antibiotic choices are limited (Sabharwal and Marchant, 2006) and the benefits 
clearly outweigh the risks of therapy e.g. Anthrax prophylaxis or infection, complicated urinary 
tract infection caused by multidrug-resistant, shigellosis (WHO, 2005; Traa et al., 2010), Gram
negative bacteria (FDA approved; Committee on Infectious Diseases, 2006). Otherwise, they are 
avoided because of concerns of emergence of bacterial resistance and arthralgia (Chalumeau et 
al., 2003; Murray and Baltimore, 2007). Other, not yet approved indication; Typhoid and 
paratyphoid fevers (Leibovitz, 2006), Gram negative neonatal sepsis/meningitis and chronic or 
acute osteomyelitis or osteochondritis (Velissariou, 2006). Among the various fluoroquinolones, 
ciprofloxacin is the most potent against pseudomonas and most safe and effective drug in 
children and neonates (Ahmed et al., 2006). 
The use of fluoroquinolones during the first trimester of pregnancy had not been associated with 
increased risk for malformations, stillbirths, preterm births or low birth weight (Bar-Oz et al., 
2009). Although both levofloxacin and moxifloxacin have been classified as category C (There 
is a positive evidence of human fetal risk, but the benefits from use in pregnant women may be 
acceptable despite the risk), they have high transplacental passage rates (Ozyuncu et al., 2010).
1.3.3 Fluoroquinolones withdrawn from the market
Owing to multiple adverse effects including severe anaphylaxis, tendon rupture, and 
cardiotoxicity several fluoroquinolones have been withdrawn (e.g. temafloxacin and 
grepafloxacin) or strictly limited in their uses (e.g. trovafloxacin) after marketing (Table 1.2
summarize fluoroquinolones withdrawn from the market). A serious idiosyncratic reaction 
profile is possibly related to the immunologically reactive 1-difluorophenyl substituent that 
characterizes temafloxacin, tosufloxacin, and trovafloxacin (Rubinstein, 2001). The withdrawal 
of temafloxacin in 1992, only 6 months after its introduction, followed the observation of 
serious adverse events that were labeled the ‘‘temafloxacin syndrome’’ (Blum et al., 1994). It
consists of hemolysis, renal dysfunction, hemolytic anemia, anaphylaxis and hepatic 
dysfunction. In 1999, trovafloxacin was withdrawn after reports of hepatotoxicity in which some 
cases required liver transplantation (Ball et al., 1999). Before this development, several studies 
had been published describing impressive clinical efficacy coupled with a good safety profile 
(Williams and Hopkins, 1998). Grepafloxacin was withdrawn from the market in 1999 because 
of its arrhythmogenic effect (Haverkamp et al., 2000). Clinafloxacin has been withdrawn 
because of phototoxicity and hypoglycemia and sparfloxacin because of phototoxicity (Zhanel et 
al., 2002).
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Table 1.2 Twelve fluoroquinolones which are no longer used or have limited significance due to 
their specific toxicities.
Fluoroquinolone Year of withdrawal Rationale for withdrawal
Enoxacin 1985 Inhibition of cytochrome p 450
Pefloxacin 1985 Tendopathies and phototoxicity
Fleroxacin 1990 Phototoxicity and CNS effects
Sitafloxacin 1991 Phototoxicity
Temafloxacin 1992 Hemolytic uremic syndrome, hypoglycemia in 
elderly patients, renal failure, and coagulopathy
Lomefloxacin 1993 Phototoxicity
Sparfloxacin 1994 Phototoxicity and  QT prolongation
Trovafloxacin 1999 Hepatotoxicity and CNS effects
Grepafloxacin 1999 QT prolongation and arrhythmia
Clinafloxacin 1999 Phototoxicity, hypoglycemia, and inhibition of 
cytochrome p 450
Gatifloxacin 2006 FDA Announces Label and indication changes 
as a result of continued reports of serious cases 
of hypoglycemia and hyperglycemia
1.3.4 Specific toxicities of fluoroquinolones
In the following section, some toxic effects of fluoroquinolones will be discussed as reported in 
the major reviews in this field. Information on undesired effects can be obtained from different 
sources including clinical trials, postmarketing surveillance, and animal studies. Adverse Events 
attributable to moxifloxacin was clinically higher than was the rate for any other 
fluoroquinolone (Shehab et al., 2008).
1.3.4.1 GIT
These include diarrhea, nausea, vomiting, distorted taste sensation and occasional abdominal 
pain. Fluoroquinolones, especially C8-methoxy fluoroquinolones, such as moxifloxacin and 
gatifloxacin, have been incriminated to be the most commonly implicated antibiotics in 
Clostridium difficile-associated colitis (CDAD) cases (Hookman and Barkin, 2009). Calculated 
attack rates were higher for the gatifloxacin than the levofloxacin-associated cases (30% versus 
17% respectively) (Gaynes et al., 2004). Increased incidence of CDAD had caused the 
development of fluoroquinolone-resistant strains (Muto et al., 2005; Loo et al., 2005). On the 
contrary, recent study showed no significant correlation between fluoroquinolone utilization and 
development of CDAD (Novell and Morreale, 2010).  Hepatotoxicity associated with the 
fluoroquinolones has become a concern with gatifloxacin (Henann and Zambie, 2001) and 
ciprofloxacin (Zimpfer et al., 2004); even levofloxacin had been associated with hepatic failure 
(Spahr et al., 2001; Coban et al., 2005). On the contrary, other fluoroquinolones were frequently 
used to replace agents in first line anti-tuberculosis regimens in patients with TB who have drug-
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induced hepatic dysfunction (Ho et al., 2009). The safety of moxifloxacin was reviewed in the 
EU and Canada following concerns over liver safety (European Medicines Agency 2008; Health 
Canada, 2010).
1.3.4.2 Cardiac
The impact of fluoroquinolones usage on the onset of arrhythmia has been investigated by a few 
epidemiological studies (Clark et al., 2001; Corrao et al., 2006; Raschi et al., 2009).
Prolongation of the corrected QT interval (QTc) is a well-known adverse effect associated with 
the use of fluoroquinolones, which can lead to potentially life-threatening arrhythmias such as 
Torsades de pointes (Tdp). This is characterized by beat-to-beat variation in the QRS complexes 
in any of the electrocardiogram (ECG) leads and occurs at rates of 200-250/ min. The clinical 
presentation includes light-headed spells, near syncope, syncope and may progress to cardiac 
arrest (Falagas et al., 2007). Risk factors for Tdp include female gender, history of familiar long 
QT syndrome, organic heart disease and congestive heart failure, bradycardia, electrolyte 
imbalance (especially hypokalemia, hypomagnesemia and hypocalcemia), renal failure, and 
hepatic dysfunction (Zeltser et al., 2003). The cardiotoxic effect is mainly mediated by blocking 
the cardiac voltage-gated potassium channels, particularly the rapid component (IKr) of the 
delayed rectifier potassium current. Inhibition of IKr delays cardiac repolarization by blocking 
outward flow of potassium ions from myocytes. IKr is encoded by human ether-a-go-go-related 
gene (HERG). The blocking ability is not the same for all fluoroquinolones being structurally 
related. The most potent inhibitor is sparfloxacin (Zünkler et al., 2006), moxifloxacin and 
gatifloxacin have an intermediate inhibitory effect on the (HERG) channel current, while 
levofloxacin and ciprofloxacin have the least inhibitory effects (Kang et al., 2001). Falagas et al.
(2007) had reported that levofloxacin and gatifloxacin were associated with significantly higher 
rates of Tdp, however still moxifloxacin appears to have the greatest potential to cause QT 
prolongation (Badshah et al., 2009; Malik et al., 2009). Gemifloxacin, ofloxacin and 
ciprofloxacin possess a less pro-arrhythmogenic effect (Anderson et al., 2001; Bischoff et al.,
2000; Kang et al., 2001; Yap and Camm, 2003; Sherazi et al., 2008). ECG data had shown that 
prulifloxacin is considered to devoid from any potential cardiotoxic effects (Rosignoli et al., 
2010).
1.3.4.3 Neuropsychiatric complications
The fluoroquinolones are an under-recognized cause of drug-induced mental status changes 
(Farrington et al., 1995). Psychiatric disorders had been reported in few studies (Leone et al., 
2003; Doussau de Bazignan et al., 2006). The overall incidence of CNS disorders associated
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with fluoroquinolones is 1–3% (Thomas, 1994). Of these, the most commonly reported 
symptoms have included dizziness, headache, and somnolence. Other, less commonly reported 
symptoms include agitation, delirium, confusion, acute organic psychosis, abnormal vision 
(Lipsky and Baker, 1999) and suicidal ideation (LaSalvia et al., 2010). Risk factors involve age, 
compromised renal function, history of seizures, and co-administration with theophylline
(Vancutsem and Schwark, 1992) or nonsteroidal anti-inflammatory drugs (Rollof and Vinge, 
1993; Quigley and Lederman, 2004). Ciprofloxacin has been linked to a variety of neurologic 
side effects such as abnormal dreams, tremor, vertigo, alcohol intolerance, ataxia, migraine, 
status epilepticus, peripheral neuropathy, and oculogyric crisis (Azar et al., 2005), psychosis had
been reported even after topical use (Tripathi et al., 2002). However, it is rarely involved in 
seizures (Jick et al., 1993; Agbaht et al., 2009), or hallucinations (Mulhall and Bergmann, 1995).
Cases involving gatifloxacin- induced psychosis or delirium in elderly patients, possibly 
suggests that this age-group is more vulnerable (Reeves, 2007). Abnormal thinking and 
hallucinations are very rare (Blondeau, 1999; Perry et al., 1999). Fleroxacin had been associated 
with unacceptable frequencies (exceeding rates of 70%) of CNS-related adverse events (Bowie 
et al., 1989).
The incidence of seizures associated with fluoroquinolones varies among the individual agents 
and is relatively rare. Sitafloxacin and levofloxacin have a weak convulsant activity that is not
enhanced by concurrent administration with anti-inflammatory drugs (Hori, 2009). The exact 
mechanism by which quinolones induces seizures is controversial. The pathophysiological basis 
for the triggering of seizures probably lies in the binding of fluoroquinolones to GABA 
receptors in the brain resulting in nervous system stimulation (Akahane et al., 1989; Domagala,
1994; Kushner et al., 2001). Binding to this receptor is strongly influenced by the side chain in
the 7-position (7-piperazine e.g., ciprofloxacin, enoxacin, and norfloxacin) and those containing 
7-pyrrolidine (e.g., tosufloxacin and clinafloxacin). Quinolones with bulky moieties, such as 
temafloxacin and sparfloxacin, bind less efficiently to GABA receptors (Owens and Ambrose,
2000; Akahane et al., 1989). Also, fluoroquinolones are thought to activate N-methyl-D-
aspartate (NMDA) channels by chelating with magnesium and removing its channel blocking 
effect (Akahane et al 1993; Schmuck et al., 1998). It is also suggested that some 
fluoroquinolones (gatifloxacin, ciprofloxacin and levofloxacin) significantly reduced brain 
glucose uptake, as suggested by reducing  GLUT1 mRNA expression, cell surface GLUT1 
protein expression and glucose transport in HepG2 cells (Ge et al., 2007 and 2009). The 
possibility of seizures initiated by levofloxacin is increased when patients are taking other 
medications with epileptogenic properties that are CYP1A2 substrates, such as mirtazapine, 
metoclopramide, and theophylline (Bellon et al., 2009).
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1.3.4.4 Ocular toxicity 
Ocular toxicity appears to be dose-dependent and results from specific fluoroquinolone 
structures. Adverse effects, such as local irritation, stinging, chemosis, conjunctival hyperemia 
and superficial punctate keratitis tend to be relatively innocuous. However, reversible corneal 
precipitation, typically seen with hourly topical administration, may not be so benign. While 
advantageous in providing a depot of slow releasing drug, delayed corneal healing and 
perforation are serious complications that may occur in approximately 10% of cases (Thompson, 
2007). Less severe, oedema of the corneal stroma occurred following topical administration and 
intravitreal injection of greater than 100 ?g ciprofloxacin (Stevens et al., 1991). Although 
reported in animals and their potential contribution to early cataract (Zhao et al., 2010), no 
reports of fluoroquinolone-induced cataracts in humans (Thompson, 2007). The intracameral use 
of moxifloxacin was not associated with ocular toxicity (Kernt et al., 2009).
1.3.4.5 Myasthenia gravis 
There have been case reports in which various fluoroquinolones except prulifloxacin (Rossi et 
al., 2009) have caused exacerbations of myasthenia gravis in patients with this underlying 
disease (Rauser et al., 1990; Mumford and Ginsberg, 1990; Vial et al., 1995). In these cases, 
muscle weakness appeared or worsened shortly after the initiation of fluoroquinolone treatment 
and improvement occurred after drug discontinuation and, in some cases, additional treatment
was needed (Moore et al., 1988; Roquer et al., 1996).
1.3.4.6 Phototoxicity
Phototoxicity is a dermatologic complication of quinolone therapy ranging from mild to severe 
reactions that usually occurs within hours of exposure to an UV light source. Singlet oxygen 
molecules and other free radicals are generated when UV light comes in contact with certain 
quinolone compounds. Under these circumstances, the resulting products were believed to attack 
cellular components, including lipid membranes, resulting in a severe inflammatory process 
(Klecak al., 1997; Tokura, 1998). These reactions were more commonly associated with the so-
called double-halogenated quinolones, namely lomefloxacin, sparfloxacin and sitafloxacin 
(Domagala, 1994; Owens and Ambrose, 2000; Stahlmann, 2002). Other agents were abandoned
during development (e.g. BAY y 3118 and clinafloxacin) because of photoxicity. Phototoxicity 
is an uncommon adverse reaction with gatifloxacin or moxifloxacin, perhaps due to the presence 
of the 8-methoxy group (Marutani et al., 1993). The photosensitizing effect of grepafloxacin is 
relatively weak and similar to that of ciprofloxacin (Stahlmann and Schwabe, 1997).
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1.3.4.7 Tendinopathy
The prevalence of the fluoroquinolones – induced tendon injury reported is low (0.14% - 0.4%) 
in an otherwise healthy population (Khaliq and Zhanel, 2005). The fluoroquinolones most 
commonly implicated are pefloxacin (37%) and ciprofloxacin (26%) (Salvi et al., 2007). Animal 
studies showed that the propensity to induce tendon lesions varies among fluoroquinolones. 
Fleroxacin, pefloxacin, levofloxacin, and ofloxacin were the most toxic, while enoxacin, 
norfloxacin, and ciprofloxacin had little or no effect (Kashida and Kato, 1997). In the 
Netherlands, a large simultaneous increase in non-traumatic tendon ruptures and 
fluoroquinolone use was observed in the period from 1991 to 1996 (van der Linden et al., 2001). 
Predisposing factors include advanced age > 60 years old, chronic lung diseases, diabetes 
mellitus, renal failure, gout, hypercholesterolemia, hyperparathyroidism (male predominance), 
low bone mineral density associated  with osteoporosis, Magnesium deficiency (alcoholism, 
dietary and renal disease), rheumatoid arthritis, and corticosteroid therapy (Childs, 2007).
However, cases were reported with levofloxacin with no predisposing factors (Gottschalk and 
Bachman, 2009; Durey et al., 2010). Tendon injury is usually presented by sudden onset of 
severe pain, tenderness, oedema, difficulty with movement of the involved area. It has been 
reported to occur as early as 2 hours after the first dose to as late as 6 months after treatment has 
been terminated (Casparian et al., 2000). The Achilles tendon is the most common site of injury, 
cited in about 90 % of patients, about 40 % bilateral. Other cases also include, patella, 
quadriceps, the hand (flexor tendon sheath and the extensor tendons of the fingers and the 
thumb) (McGarvey et al., 1996). The pathogenesis of quinolone-induced tendinopathy was
considered to be multifactorial. Theories postulating the causes of tendinopathy were ischemic 
influences, matrix degrading phenomenon, and toxic changes on collagen fibers (Kowatari et al., 
2004; Gold and Igra, 2003).
1.3.4.8 Arthropathy
Arthropathy has been reported with various fluoroquinolones, particularly in children where 
ciprofloxacin and pefloxacin were involved (Grady, 2005). However, ciprofloxacin did not 
cause clinical arthropathy and growth impairment even at 1 year of follow-up (Drossou-
Agakidou et al., 2004). The lower chondrotoxic risk associated with the use of quinolones in 
children explained by some authors as differences in velocity of growth in experimental animals 
and human (Sendzik et al., 2009). So, fluoroquinolones are currently reserved for use in children
as mentioned before (1.3.2).
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1.3.4.9 Anaphylaxis 
Interestingly, in a considerable number of cases, anaphylaxis was reported to occur after the first 
intake of a particular fluoroquinolone. In particular, ciprofloxacin (received marketing 
authorisation in the USA in 1987) by 1988, a total of 15 cases of anaphylaxis or anaphylactoid 
reactions associated with its use had been received by the US FDA (Davis et al., 1989). Most 
patients are sensitized to more than one fluoroquinolone, suggesting an extensive cross-
reactivity between the different molecules as all of them share a common core structure (Scherer
and Bircher, 2005). Anaphylaxis (type I, Ig E-mediated reactions occurring within 1 hour of 
administration) was more rarely found with quinolones than ????? ?????? ???????????? ????? ??? ?
lactams. Forms of type I reactions include urticaria, angioedema, and anaphylactic shock. The 
only definitive test for diagnosis is the challenge with the drug itself (Aberer et al., 2003), which 
is a risky proposition, because fatalities have been reported (Peters and Pinching, 1989) although 
basophil activation test showed to have a good sensitivity and specificity with quinolones
(Aranda et al., 2010).
1.3.4.10 Immune-related idiosyncratic reactions
These include hemolytic – uremic syndrome, hemolytic anemia, thrombocytopenia, leucopenia, 
acute interstitial nephritis, acute hepatitis, acute cholestatic jaundice, Steven-Johnson (life-
threatening condition affecting the skin in which cell death causes the epidermis to separate 
from the dermis) and Lyell syndromes (Toxic Epidermal Necrolysis), fixed drug eruption, 
cutaneous vasculitis, macula-papular exanthema, acute pancreatitis, serum-sickness like 
syndrome, angioimmunoblastic lymphadenopathy, acute exanthematous pustulosis, and 
eosinophilic meningitis (Campi and Pichler, 2003). Fixed drug eruptions have been observed 
with ciprofloxacin, tosufloxacin, norfloxacin, and ofloxacin (Hager et al, 2009). Single case 
reports exist on patients with toxic epidermal necrolysis or Stevens-Johnson syndrome attributed 
to different fluoroquinolones. Most often ciprofloxacin was the responsible agent, but also 
trovafloxacin, ofloxacin, and levofloxacin have been reported (Jongen-Lavrencic et al., 2003).  
Animal studies suggest that quinolones were assumed to stimulate both mast cells and basophils 
to release histamine (Scherer and Bircher, 2005). Gatifloxacin, although devoid of 
photosensitivity reactions, may initiate idiosyncratic hypersensitivity reaction to cause Radiation 
Recall Dermatitis (RRD) (Jain et al., 2008). Several cases of cutaneous vasculitis due to 
ciprofloxacin, ofloxacin, and levofloxacin drug therapy have been reported (Maunz et al., 2009).
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1.3.4.11 Legal implications
Adverse drug reactions continue to cause injury and harm to patients regardless of careful 
evaluation, prescription, and drug administration. This problem did grow into a cottage industry 
for malpractice lawyers. What makes fluoroquinolones special is that side effects appear or
worsen for even months after the drug has been discontinued. A good example is the 
musculoskeletal injury associated with fluoroquinolones. It is the responsibility of the physician 
to be aware of the risks of fluoroquinolones. A physician’s best defense in case of malpractice or 
negligence is to demonstrate that practice was within a reasonable standard of care and that any 
deviation from approved indications was documented at the time of care with literature support. 
Action against the practitioner may also be minimized by ensuring adequate patient informed 
consent especially for patients with risk factors (Kaufman et al., 1994).
1.4 Fluoroquinolones and dysglycemia
The first case report of hypoglycemia was in a diabetic patient; associated with enoxacin 
(Kobayashi et al., 1991) followed by ciprofloxacin (Whiteley et al., 1993), lomefloxacin (Suda 
et al., 2000); and even hypoglycemic coma with norfloxacin (Haruhara et al., 2000). Oliphant 
and Green (2002) published the first review that acquaints gatifloxacin as a causative agent of
dysglycemia if used concomitantly with antidiabetic agents. Further cases reported by Menzies 
et al. (2002), and Baker and Hangii (2002). This caused a revision of the package insert to 
include warnings of serious dysglycemias (Lewis-Hall, 2006). Levofloxacin was suspected for 
22 domestic reports of dysglycemia from 1997 to 2006 in Canada (Hunt, 2007). As a 
consequence of hypoglycemia, some cases were complicated by anoxic brain injury (Lawrence 
et al., 2006) or by pontine myelinolysis and quadriplegia (Vallurupalli et al., 2008). Fatal 
hypoglycemia was reported with levofloxacin (Friedrich and Dougherty, 2004; Singh et al., 
2008). Both hypoglycemia and hyperglycemia have been recognized with moxifloxacin use 
(Avelox®, package insert, 2002; Smith and Lomaestro, 2003). However, no life threatening 
reports of hypoglycemia were reported so far neither with gemifloxacin (Ball et al., 2004), nor
with moxifloxacin (Gavin III et al., 2004). Donaldson et al. (2004) first correlated gatifloxacin 
and symptomatic severe hyperglycemia. This was followed by many case reports (Ambrose et 
al., 2003; Arce et al., 2004; Happe et al., 2004; Blommel and Lutes, 2005; Beste and Mersfelder, 
2005; Yip and Lee, 2006; Ovartlarnporn and Jongjaroenprasert, 2007). Risk factors for 
hypoglycemia in patients without diabetes are older age, low plasma albumin concentration, 
liver disease, malignancy, chronic heart failure, and concomitant use of oral hypoglycemic 
(Owens, 2005). Risk factors for hyperglycemia may include diabetes, renal impairment (Mohr et
al., 2008), sepsis (Orlander and Serrao, 2004), and old age (Biggs, 2003). While hypoglycemia 
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is very infrequent, as highlighted by the studies of Mohr et al. (2005) and Graumlich et al. 
(2005) , hyperglycemia occurring more often. As opposed to the timing of hypoglycemic events, 
review of several case reports revealed that fluoroquinolone-associated hyperglycemia has 
generally occurred later in treatment, usually after 4 days of therapy, and with higher doses 
(Catero, 2007). Fluoroquinolones, as well as other antibacterials have been reported with 
dysglycemia (hypo or hyperglycemia) in case reports and databases of adverse drug reactions 
(Basaria and Cooper, 2005; Strevel et al., 2006; Jose et al., 2007). Nevertheless, apparently the 
risk of a clinically relevant dysglycemia is variable among fluoroquinolones. The rates of severe 
hypo- and hyperglycemia were significantly greater with gatifloxacin 1.1% while for 
levofloxacin, ciprofloxacin (0.3% for each), and moxifloxacin (0.2%) (Park-Wyllie et al., 2006; 
Lodise et al., 2007; Aspinall et al., 2009; Van Bambeke and Tulkens, 2009). In phase II and III 
studies, clinafloxacin was associated with a 4% frequency of hypoglycemia versus 1.1% in 
comparator-treated patients (Garber et al., 2009). Spontaneous reporting of adverse drug 
reactions (ADRs) suffers from underreporting perhaps as newer agents are more likely than 
older agents to be reported due to enhanced prescriber and media attention which is known as 
the Weber effect (Hartnell and Wilson, 2004). Data source alone is unreliable to quantify risk 
assessment because preclinical testing, phase I-III trials, and postmarketing surveillance all have 
limitations in their ability to identify infrequently occurring toxicities (Owens and Ambrose, 
2005). The Naranjo probability rating scale (Naranjo et al., 1981) revealed that fluoroquinolones 
was the probable cause in many cases (Zvonar, 2006). Therefore, glucose as well as drug 
monitoring is highly recommended in patients with long-term use of steroids, cyclosporine, and 
decreased creatinine clearance and diabetics (Khaira et al., 2009). The critical question is that 
fluoroquinolones per se are culpable of producing dysglycemia? The theory of a possible drug-
drug interaction has been considered among many case reports involving fluoroquinolones and 
antihyperglycemic medications. Glyburide was the most often implicated antihyperglycemic 
drug, accounting for five of these cases. The remaining interactions involved glimepiride, 
pioglitazone (with glyburide), and repaglinide. However, only ciprofloxacin is completely 
metabolized by cytochrome P450 (CYP) which might explain severe hypoglycemia due to 
interaction with glyburide (Roberge et al., 2000; Lin et al., 2004; Kelesidis and Canseco, 2010).
However, it was found that moxifloxacin, and gatifloxacin were negligible inhibitors to 
cytochrome P450 isoforms; CYP1A2 and CYP2C9 (Zhang et al., 2008).  Still, severe and 
resistant hypoglycemia was attributed to interaction between gatifloxacin and sulfonylureas
(LeBlanc et al., 2004). Dosage reduction seems as ineffective strategy to prevent the 
hypoglycemic event associated with gatifloxacin or levofloxacin in patients with renal 
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insufficiency (Garber et al., 2009). So, it is unlikely that the pharmacokinetics of these drugs 
could sufficiently explain the dysglycemic episodes.
Fluoroquinolones appear as indispensible antimicrobial agents despite of the emergence of 
resistance. Several agents had been examined as inhibitors of mycobacterial infections
especially tuberculosis as one of the re-emerging diseases (Onyenwenyi et al., 2008; 
Senthilkumar et al., 2009). Though Bristol-Meyers Squibb has voluntarily withdrawn 
gatifloxacin from the US and Canadian drug markets (Lewis-Hall, 2006), it is still marketed in 
other parts of the world. So, it is very important to search for the possible mechanism clarifying 
the potentially life threatening dysglycemic episodes and also there is deep need for 
development of new compounds devoid of such effects.
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2. Aim of work
Pancreatic ? cells regulate the whole body metabolism by secreting the hormone insulin in 
response to raised levels of blood glucose. However, the mechanisms underlying (GSIS) are not 
completely understood. It is thought that some fluoroquinolones produce endocrine toxicity in 
the form hypoglycemia via blockade of KATP channels. Gatifloxacin, in particular has been 
shown to produce both hypo- and hyper-glycemia. So, the aim of the present study is to answer 
the following questions:
i. Is that toxicity related to change in cellular calcium level, as can be expected from KATP  
channel blocking agents? If so, could that lead to ? cell death (cytotoxicity)?
ii. Is there any peculiar morphological feature for ? cells and /or pancreatic islets that could 
be attributed to fluoroquinolones toxicity?
iii. Is that combination of hypo- and hyper-glycemia specific toxicological feature for 
gatifloxacin or could be induced by other fluoroquinolones?
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3. Materials and methods
3.1 Equipment
Equipment Model Company
Water purification system Ultra clear Arium 611 VF Sartorius
Autoclave Vx-120 and DX-90 Systec GmbH
Balance BP 210 D Sartorius, Germany
pH meter 766 Climatic Knick
Centrifuge Biofuge  Primo R 
Benchtop Heraeus
Sterilizer (Oven) MOV 212 SANYO
Balance BP 210 D Sartorius, Germany
Heated Circulator water bath 1003 GFL,GmbH
Clean bench Laminar Air HBH Heraeus
Magnetic rotator RCT basic IKA-Labortechnik
Mini-shaker MS1 IKA
CO2 incubator MCO-18AIC SANYO
Stereomicroscope STEMI 2000 with KL 
1500 light source
Carl Zeiss
Shaking Water bath ST1-338 Edmund Buehler
Peristaltic pump Varioperpex II 2120 LKB Bromma
Dichroic beam splitter TK 405 Leitz
Photon counting unit (Power 
supply, pulse forms unit, and 
CTM-05 counting board)
3460-04 Hamamatsu Photonics
Compound microscope Orthoplan Leica/Leitz
Cooled digital CCD camera Theta electronics GmbH
Mercury arc lamp ST41 Heraeus –Hanau
Xenon lamp L2274 Hamamatsu
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3.2 Basic medium
3.2.1 Krebs-Ringer-Bicarbonate-Medium
The basic medium for the isolation and the preparation of the pancreatic islets as well 
as the following dissociation into single ? cells is a modified Krebs-Ringer-
Bicarbonate-Buffer abbreviated as mKRB (Panten et al., 1977). The modification 
consists of the addition of HEPES solution which provides rather steady pH of 7.4 for 
a longer period. Lernmark had shown that the substitution of an adequate portion of
the necessary bicarbonate concentration by the organic HEPES buffer prevented the 
alkalinisation of the medium as a result of the release of CO2 (Lernmark, 1974)
For the preparation of 2 L of mKRB, the following amounts of organic matters and 
inorganic salts were dissolved in autoclaved pyrogen- free deionised water to reach the 
final concentration shown in the right column.
1) 752.74 mg CaCl2 ? 2 H2O (Merck, MW  147.02)              2.5 mM
2) 700.77 mg KCl (Merck, MW  74.55)  4.7 mM
3) 326.26 mg KH2PO4 (Merck, MW  136.09) 1.2 mM
4) 591.55 mg MgSO4? 7 H2O (Merck, MW  246.48) 1.2 mM
5) 13.44 g NaCl (Roth, MW 58.44) 115 mM
6) 3.36 g NaHCO3 (Merck, MW 84.01) 20 mM
7) 1.98 g D-Glucose monohydrate (Merck, MW 198.17)            5 mM
8) 4.76 g HEPES (Roth, MW 238.31) 10 mM
9) 2.0 g Albumin (Serva, MW 66382) 0.1 % (w/v)
Albumin was added lastly to avoid excessive foam formation during stirring. The pH value of 
the resultant mKRB was adjusted to 7.4 by using 1N NaOH solution and was filtered under 
sterile conditions (Prefilter: 13400-130-K; Main filter: 11107-142-G, Sartorius).
The resultant mKRB was filled into sterile containers of 100 ml portion and stored at a 
temperature of 2 - 8 °C for a period maximally 4 weeks. Since prolonged storage can alter pH 
value, it is worthwhile to readjust pH before use using 1N NaOH or 1N HCl solutions.
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3.2.2 Solutions for islets and islet cells isolation and culture medium
3.2.2.1 Sodium hydroxide-solution 1 N 
Sodium hydroxide 40 g (Merck, MW 40) completely dissolved in a volume of 1L distilled 
water. 
3.2.2.2 Collagenase P-solution
Collagenase P is prepared from the extracellular culture filtrate of a special Clostridium 
histolyticum strain. It is supplied as lypholisate and has a considerable lot to lot variability of the 
enzymatic activity (Yamamoto et al., 2007). To optimize islet isolation, both the amount of 
collagenase as well as period of digestion were adjusted for every batch (de Haan et al., 2004).
Depending on the activity of the used batch, 1.0 -1.5 mg / 2 ml solution was used of collagenase P
(Serva Electrophoresis GmbH, group I).  To keep it stable, the enzyme was stored at a temperature 
of 2 °C and immediately before usage, dissolved in the suitable volume of freshly prepared mKRB
(Bucher et al., 2004).
3.2.2.3 Ca2+ -free solution for the dissociation of the isolated islets into ? cells 
The contents of the Ca2+ free medium are the same as for mKRB except for the omission of 
CaCl2 and the addition of 19.02 mg EGTA (Sigma, MW 380.4) to reach a ready to use
concentration of 0.5 mM. 
3.2.2.4 Collagen-solution used for the islets culture
The cover slips (diameter 25 mm, thickness 0.13 - 0.17 mm, Menzel, Braunschweig)
were first rinsed with distilled water and left to dry, and then sterilized by heating for 
40 minutes at 180 °C.  For cultivation of pancreatic islets, collagen solution (1.2-1.3 
??) was evenly distributed on middle of cover slips. For preparation of 2 ml of collagen 
solution, 1 mg of collagen type 1 (Sigma) was weighed in a sterilized Eppendorf cup 
to be dissolved in a sterile 0.2 % acetic acid immediately sterilized before addition 
using a Filtropur 0.2 S syringe filter (Sarstedt, Germany) (Lenzen et al., 2000). 
Subsequently, the collagen was dissolved in an ultrasonic bath. The final solution was 
stored at 4 °C. 
3.2.2.5 Culture medium RPMI 1640
Studies of optimal culture conditions demonstrated that RPMI 1640 with serum maintains 
glucose-stimulated insulin secretion in murine islets (Andersson, 1978). RPMI contains 
inorganic nutrient salt and buffer systems, vitamins, provitamins, as well as essential amino 
acids, Phenol-red and Glutathione. During the first two hours in cell culture, (the initial adhesive 
phase) the pancreatic islets were incubated with RPMI medium containing 10 mM glucose. For 
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1 L of solution to be used, 8.44 g RPMI 1640 (Gibco), 1.98 g glucose and 2.0 g NaHCO3
(Merck) were dissolved in 0.9 L distilled water. The pH was adjusted further if necessary by 
adding either 1N HCl or 1N NaOH until pH 7.2 was obtained. Penicillin and streptomycin were 
added to give a final concentration of 100 IU / ml penicillin and 100 ?g/ml streptomycin 
(Gibco). After setting the pH at 7.2, the medium was immediately filtered using a Sartorius 
Vacuum flask filter system with a Sartorius glass prefilter (Prefilter: In 13400-130- K, ???????
Sartorius Cellulose acetate filter: 11107-142-G, Sartorius) and stored at 2 – 8 °C. The resultant 
RPMI 1640 medium was dispensed into 90 ml sterile bottles. Immediately before use, the 
medium was supplemented by 10 ml of a heat-inactivated fetal calf’s serum (FCS) (Gibco) with 
change of pH to 7.4. In case of the pancreatic islets, 2.5 ml of RPMI medium (5 mM glucose) 
was added after a period of 3-4 h.
3.2.2.6 Culture medium RPMI 1640, modified with 5 mM glucose
D-glucose monohydrate (99.1 mg) was dissolved with 844.0 mg of RPMI 1640 glucose-free as 
well as 2.0 mg NaHCO3 (Merck) in a volume of 90 ml distilled water. Further conditions for 
preparation and storage were the same as those mentioned in 3.2.2.5.
3.2.3 Analysis solutions of the used drugs
The solutions of the examined fluoroquinolones were prepared from the stock solutions. 
Ciprofloxacin and Moxifloxacin are available in the form of drip solutions in bottles kept under 
sterile conditions and away from light according to the recommendations of the manufacturer. 
Gatifloxacin is available in the form of powder.
3.2.3.1 Ciprofloxacin
1-cyclopropyl- 6-fluoro- 4-oxo- 7-piperazin- 1-yl- quinoline- 3-carboxylic acid 
One bottle of 50 ml ciprofloxacin-drip solution (Ciprobay®, Bayer) was used as a stock solution. 
It contains 127.2 mg ciprofloxacin lactate and correspondingly, 100.0 mg ciprofloxacin (MW 
331.35). Immediately before experiments, 100 or 500 ?M solutions were prepared by diluting 
833 ?l or 4.16 ml, respectively from the bottle to make the final volume of 50 ml.
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3.2.3.2 Gatifloxacin
1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid
It is available as a pure substance (MW 375.4, Grünenthal GmbH, Aachen, Germany). To 
prepare 100 or 500 ?M solution, 1.31 or 6.57 mg of gatifloxacin powder was dissolved in 35 ml 
of mKRB, respectively.
3.2.3.3 Moxifloxacin
1-cyclopropyl-7-[(1S, 6S)-2, 8-diazabicyclo [4.3.0] non-8-yl]-6-fluoro-8-methoxy-4-oxo- quinoline-
3-carboxylic acid
It is available as an infusion solution (Avalox®, Bayer) in a 50 ml bottle containing 87.36 mg 
moxifloxacin hydrochloride (MW 401.44). The concentrations used for the measurements (100 
and 500 ?M) were made by mixing 1.37 or 6.85 ml in mKRB to reach the final volume of 40 ml, 
respectively.
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3.2.4 Perifusion solutions of the ratiometric fluorescence microscopy
3.2.4.1 HEPES-buffered Krebs-Ringer-Bicarbonate solution (Krebs-Ringer-Basic medium)
For the perfusion experiments, mKRB medium was prepared by adding the below given 
volumes of stock solutions to give a volume of 1 L.
1. Stock solution 1 (0.90 % NaCl): 18.0 g sodium chloride (Merck) was dissolved in 2 L
distilled water. 200 ml stock solution yield a final concentration of 115 mM NaCl.
2. Stock solution 2 (1.15 % KCl): 5.75 g potassium chloride (Merck) was dissolved in 500 
ml distilled water. 8 ml stock solution yields a final concentration of 4.7 mM KCl 
3. Stock solution 3 (1.62 % CaCl2? 2H2O): 8.10 g calcium chloride (Merck) was dissolved 
in 500 ml distilled water. 6 ml stock solution yields a final concentration of 2.5 mM 
CaCl2.
4. Stock solution 4 (2.1 % KH2PO4): 5.27 g potassium dihydrogen phosphate (Merck) was
dissolved in 250 ml distilled water. 2 ml stock solution yields a final concentration of 1.2 
mM KH2PO4
5. Stock solution 5 (3.82 % MgSO4?7H2O): 9.55 g Magnesium sulphate (Merck) was 
dissolved in 250 ml distilled water. 2 ml stock solution yields a final concentration of 1.2 
mM MgSO4.
6. Stock solution 6 (1.30 % NaHCO3): 13 g sodium bicarbonate (Merck) was dissolved in 
a volume of 1000 ml distilled water and was then bubbled for a period of 30 min with 
CO2. 34 ml stock solution yields a final concentration of 20 mM NaHCO3
7. Stock solution 7 (6.5% fatty acid-free albumin, 7.74% HEPES, 154 mM NaOH): 32.5 g 
of fatty acid-free bovine serum albumin (Serva) was dissolved in 200 ml distilled water. 
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Then 38.7 mg HEPES (Sigma) was dissolved in 125 ml distilled water. To this solution 
77 ml 1N NaOH (Merck) were added. Then, these two solutions were transferred in a 
500 ml flask and it was filled up with distilled water to 500 ml. This solution was divided 
in 10-ml portions and stored at -20 °C. 8 ml stock solution yields a final concentration of
4.7 mM NaOH, 10 mM HEPES and 0.2 % Albumin.
For the microfluorometric measurements, pure HEPES solution was used instead of stock 
solution 7 to prevent formation of foams by albumin since the experiments require bubbling 
with Carbogen (mixture of 5 % CO2 and 95 % O2), for 20 - 25 minutes directly before and 
continuously during the experiments.
3.2.4.2 Carbonylcyanide-m-chlorophenylhydrazone (CCCP)
CCCP stock solution (20 mM): 4.09 mg of CCCP (Sigma, MW 204. 60) were dissolved in 1 ml 
DMSO. CCCP test medium (5 ????? ???? ??? ????? ?????? ?????????was added to 10 ml of a 
glucose-containing mKRB.
3.2.4.3 Sodium Azide (NaN3) 
NaN3 stock solution (500 mM): 32.5 mg of NaN3 were dissolved in 1 ml water.
NaN3 test medium (5 mM): 100 ?l of stock solution was added to 10 ml of mKRB.
3.2.4.4 D- 600 (Methoxyverapamil) 
To prepare a 5 mM stock solution, 26 mg D 600 (Sigma, MW 521) was dissolved in a volume of 
10 ml distilled water. Preparation of 50 ?M D-600 solution was made by the dilution of 300 ?l 
of the stock solution with 30 ml with mKRB.
3.2.4.5 Diazoxide
Stock solution (300 mM) was prepared by dissolving 69.21 mg of diazoxide (Sigma, MW
230.7) in 1 ml DMSO. Diazoxide test medium (300 ?M): 100 ?l of the stock solution was added 
to 100 ml mKRB.
3.2.4.6 Tolbutamide 
Stock solution (50 mM) was prepared by dissolving 13.51 mg Tolbutamide (Serva, MW 270.3)
in 1 ml 0.1N NaOH. Tolbutamide ???????????? ????? ????? ???? ??? of the stock solution were 
added to 10 ml mKRB.
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3.2.4.7 Potassium chloride solution 
To prepare 40 mM KCl solution, 24.52 mg KCl (Merck, MW 74.56) was dissolved in 10 ml 
mKRB, which already contains an amount of 4.7 mM KCl.
3.2.4.8 Glucose-substituted (5 mM and 10 mM) Krebs-Ringer-Basic medium
D-glucose monohydrate (Merck MW 198.17) 99 mg, 198.2 mg and 396.4 mg were dissolved in 
a volume of 100 ml of mKRB, to obtain 5, 10 and 20 mM glucose concentrations in the 
perifusion medium, respectively.
3.2.5 Solutions of fluorescent indicator
3.2.5.1 Fura- 2/AM (Acetoxymethyl ester)
For the production of the 1 mM stock solution 50 ???????- 2/AM (Mobitec; Göttingen, MW 
1001.86) was ????????????????????????????????????????????????????????????????????was stored 
away from light at a temperature of 4 °C and was used for a maximum period of 3 weeks. To 
load the isolated ? cells, 2 ??????the stock solution was ???????????????????????????????????????
mKRB (see 3.2.4.1???????????????????????????????????????- 2/AM is achieved. 
3.2.5.2 Fura-PE3/AM
Fura-PE3/AM stock solution (1 mM):  0.5 mg Fura-PE3/AM (Mobitec- Göttingen, MW 1258) 
was dissolved in 397 ??? ????? ???? ???????? ??? ??? ??? ?????? ????????? ??? ??????? ????-PE3/AM
i?????????????????????????????????????-PE3/AM stock solution was ???????????????????????the 
glucose-containing mKRB.
3.2.5.3 Rhodamine 123 
Rhodamine 123 (Sigma) was dissolved in DMSO at a concentration of 1 mg/ml and stored at 
4 °C. 
3.3 Experimental Animals
3.3.1 NMRI-albino mice
NMRI mice (12-14 weeks old, female) were used as donor animals for the isolation of the 
pancreatic islets and ? cells (Harlan Winkelmann or Charles River). They were kept in Macrolon 
cages in air-conditioned rooms (25 °C) at a constant day/night cycle (12 -12) and they received 
standard pellet feed and water ad libitum. The NMRI albino mice were originally established in 
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1937 as a Swiss Out breeding mice at the National Institutes of Health and then were transferred 
to the Naval Medical Research Institute, hence the name.
3.3.2 SUR1 knock-out mice 
In order to investigate the KATP channel-independent effects of fluoroquinolones, SUR1 knock-
out mice were used. They were kindly provided by Lydia Aguilar-Bryan and Joseph Bryan 
(Pacific Northwest Research Institute, USA). Similar to the NMRI-albino, these mice were kept 
with 12 hours day and night rhythm at a temperature of 25 °C and received the standard food 
and drinking water ad libitum. Both strains were kept at Animal care facility, TU-Braunschweig. 
Principles of laboratory animal care were carried out in accordance with the standards 
established by the European Communities Council Directive.
3.4 Islets isolation and cell culture
3.4.1 Pancreatic islets isolation
The two most prevalent approaches for isolating islets from rodent pancreatic tissue differ, 
primarily, in the way collagenase enzyme was introduced to the pancreatic tissue. The primary 
objective of these methods is to provide a large number of tissue-free and intact functioning 
pancreatic islets as well as ? cells (Ravier and Rutter, 2010). 
1. The "conventional" digestion method (Moskalewski, 1965, Lacy and Kostianovsky, 
1967; Lernmark, 1974) was based on cutting the pancreas into small pieces before the 
digestion with collagenase.
2. The injection method, in which the collagenase solution was injected into the bile duct to 
distend the pancreas via the pancreatic duct prior to excision of the pancreas from the 
sacrificed mouse (Gotoh et al., 1985; Zimny et al., 1993).
3.4.1.1 The ‘conventional’ method
First the mKRB and culture media should be prepared and the shaking water bath switched on to 
reach a temperature of 37 °C within 20 minutes. An NMRI mouse was sacrificed by cervical 
dislocation. The skin was disinfected with ethanol (70 %) and then the skin, the subcutaneous 
tissue and abdominal muscle were cut open. The pancreas was then completely excised and was 
transferred to a glass vessel containing mKRB (5 mM glucose). Before the beginning of the 
collagenase digestion, the tissue was made free from adjacent fat and then transferred in 2 ml 
mKRB solution to be cut with scissors into very small pieces for approx. 3 - 5 minutes. Then the 
tissue suspension was transferred to a glass vessel containing 1 mg collagenase. This glass 
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vessel was then shaken in a water bath and with a frequency of 328/min at 37 °C. The digestion 
was stopped just after 7 - 9 minutes (depending on the activity of the collagenase batch) by 
diluting the contents using mKRB and then shaking vigorously by hand (approx. 10 s). This 
suspension was left for about 5 minutes, sedimented to the base leaving the supernatant to be 
aspirated with a vacuum pump and the glass container was filled again with the glucose-
containing mKRB. The remaining tissue was transferred to a black Petri dish for pancreatic
islets to be freed from the surrounding exocrine tissue, under the stereomicroscope within about 
30-40 minutes with the help of two milled needles. The islets appear spherical and white, 
approximately 50–250 ???????????????????????????????????????????????e white color of the islets 
in comparison to the relatively darker exocrine tissue, allow for rapid identification of the islets.
An average of 60 islets per mouse could be obtained using this method. 
3.4.1.2 Injection method
According to the injection method used by Gotoh et al. (1985) and Zimny et al. (1993), 1 mg 
collagenase was dissolved in 2 ml of mKRB medium. This solution was put in a 3-ml plastic 
syringe (Injekt, Braun), which lead this syringe with a sterile needle (BD Microlance) to be kept 
on ice. After sacrification, the mouse was then fixed on a clipboard with the caudal part showing 
away from the preparator. The peritoneal cavity was opened as described above. All the organs 
were placed on the left side to let the pancreatic duct visible. The punctum where the pancreatic 
duct joins the duodenum could be identified as a milky white area on the duodenum. The 
punctum was closed with a vascular clamp, which prevents the collagenase from escaping from 
the pancreas through the intestine. Under the stereomicroscope, the cooled collagenase was 
injected in the tense bile duct so that the solution passes retrograde via the pancreatic duct to fill 
the pancreas as shown in (Fig 3.1). The pancreas was separated carefully, without cutting it to 
prevent the collagenase from escaping. The intestine must not be cut, to avoid contamination.
The pancreas was removed using a sterilized forceps and was transferred into a 10-ml plastic 
Falcon tube (Sarstedt), which was kept on ice. This tube was then left for 8 - 9 minutes in a 
water bath at 37 °C to initiate digestion and then, with gentle shaking by hands for 60-90 
seconds till the suspension looks homogenous with no or few clumps. Thereafter, digestion was 
then terminated with 5 ml of cold mKRB medium. Secondly, the digested pancreas was 
centrifuged for 15 seconds at 300 g (1340 rpm), the supernatant was removed, and the sediment 
was washed with mKRB medium and removed and centrifuged again. The digested pancreas 
was then filled with mKRB medium and transferred into a black dish.
For the production of single cells, the islets were collected (as described above) to be transferred 
in 5 ml of Ca2+ free solution for 10 minutes, during which the contents were vortexed twice for 
3. Materials and methods 29
one minute in the beginning and at the end, and then centrifuged at 1000 rpm for one minute. 
Then, under the clean bench, the supernatant was aspirated and the cells were re-suspended in 
RPMI 1640 containing 10 mM glucose, vortex for 10 seconds, centrifuged as above then the 
supernatant was removed leaving small volume which contains most of the ? cells. The cells 
were incubated in a cell culture incubator 2 hours and half to allow the maximum numbers of 
cells in the centre of the plastic Petri dishes (Sarstedt) to attach to the cover slip before 2.5 ml 
RPMI 1640 medium with 5 mM glucose (3.2.2.6) was added for each Petri dish.
Clamp
Liver
duodenum
Pancreas filled with
collagenase solution 
Stomach
Figure 3.1 The injection method for isolation of the pancreatic islets from NMRI mouse. Scheme of 
collagenase injection into a mouse pancreas (Right). The pancreatic duct was clamped at the point 
where it joins the duodenum intestine. Then, 3 ml of collagenase was injected via the bile duct to fill the 
pancreas of NMRI mouse (Left).
3.4.2 Cultivation of isolated pancreatic islets  
Under sterile conditions (clean bench), small Petri dishes were marked on the bottom by a circle 
to adjust the place for the cover glass, where collagen solution (Lenzen and Peckmann, 2001)
was spread and left to dry for about 10 minutes. Then each a single pancreatic islet was
transferred to each precoated cover glass ??? ?? ??????? ??? ??? ??? ????-culture medium 
(containing 10 mM glucose). The islets were kept in the incubator for a period of 3 - 4 h. After 
this attachment period, 2.5 ml of the RPMI-medium containing 5 mM glucose was added (see 
chapter 3.2.2.6). 
3.5 Microfluorometric measurement 
3.5.1 Basic considerations for fluorescence measurements
Fluorescence involves the absorption of light to generate an excited state in a molecule which 
then emits light upon return to the ground state. This process is illustrated in the Fig 3.2A, 
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showing the major molecular pathways of a fluorophore in a Jablonski diagram. The lowest 
energy state, the ground state, is denoted by S0. This state is for most organic molecules an 
electronic singlet, in which all electrons have opposite spin. All chemical compounds absorb 
energy, which causes excitation of electrons bound in the molecule, such as increased 
vibrational energy or, under appropriate conditions, transitions between discrete electronic 
energy states (S1, S2, . . etc.). For a transition to occur, the absorbed energy must be equivalent 
to the difference between the initial electronic state and a high-energy state. This value is 
constant and characteristic of the molecular structure. This is termed the excitation wavelength. 
If conditions permit, an excited molecule will return to ground state by emission of energy 
through heat and/or emission of energy quanta such as photons. The energy difference between 
the lowest energy peak of absorbance and the highest energy of emission is called the Stokes 
shift (Fig 3.2B). The fluorescent output is determined by the efficiency of light absorption and 
the amount of light emitted relative to what was absorbed (characterized by its quantum yield).
A B
Figure 3.2 Jablonski diagram and Stokes shift. A) Jablonski diagram illustrating the major molecular 
pathways of a fluorophore upon absorption of a single photon. If the photon emission (shown in short 
wavelength blue in the diagram) occurs between states of the same spin state (e.g. S1 ---> S0) this is 
termed fluorescence. If the spin state of the initial and final energy levels are different (e.g. T1 --> S0), 
the emission is called phosphorescence (shown in longer wavelength red). B) Stokes shift is shown 
between the excitation and emission maxima (Wolf, 2007).
3.5.2 Principles of epifluorescence microscopy
Epifluorescence microscopy is a method of fluorescence microscopy in which both the excitation 
and emission light travel through the objective. Using a matched optical set that consists of an 
excitation filter, a dichroic beam splitter and a barrier filter, the epi-illuminator allows only light of 
the correct short, exciting wavelength to strike the preparation and only light of the longer, emitted 
wavelength to reach the eyepiece, detector or the camera (Fig. 3.3). In order to generate enough 
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excitation light intensity to furnish a level of emission capable of detection, powerful light sources 
are needed, usually arc (burner) lamps either xenon or mercury powered by a D.C. power supply.
Xenon arc lamp is typically referenced using the registered trademark as XBO lamps (X for Xe or 
xenon; B is the symbol for luminance; O for unforced cooling). It contains in its emission spectrum, 
the excitation wavelengths of fluorophore Fura-2 and Rh123 and provides a largely continuous and 
uniform spectrum across the entire visible spectral region (300 - 650 nm). 
To produce a dual wave length excitation, the following set up was employed:
An internal reflecting mirror is incorporated in the lamp house so that to produce a collimated light 
beam of high intensity. The lamp is coupled to two different quartz fibers light guide, which provide
the necessary excitation of the indicator Fura-2 at two different wavelengths. These two fibers are 
electronically controlled by two shutters (Uniblitz shutter control unit with VMMD-1) with a 
programmable frequency to the excitation light. By this way, illumination will be blocked when 
data is not required and photobleaching could be avoided. The chosen wavelength (the 
monochromatic light) was then passed in the diffraction grating of quartz fibre light guide. By this 
way, light of a single wavelength was used each time the shutter opens (in case of Ca2+, 340 and 
380 nm).
Figure 3.3 Illustration of the light path of the epifluorescence microscope. The light source used 
either high pressure mercury or xenon lamps. The production was made monochromatic light by 
excitation filter.
The dichroic mirror (also "chromatic beam splitter", abbreviated to CBS) is a key element of the 
fluorescence microscope and is used to separate the excitation and emission light paths. It 
reflects wavelengths of light below the transition wavelength value (into the objective) and 
transmits wavelengths above this value (to the eyepiece or detection system).
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The dichroic mirror was mounted above the object at 45° in the light path and monochromatic 
excitation light (340 nm to 380 nm) is deflected by 90° in the direction of the object, which 
supported the separation between excitation and fluorescence light. This beam splitter reflects 
light of short-wave radiation (470 nm, i.e., the fluorescence excitation light) and allows longer-
light (> 500 nm, i.e. the emission of fluorescent light) to pass, so that Fura-2 fluorescence light
(maximum 510 nm) could pass through the dichroic mirror. The use of a single lens system 
provides an optical system focusing the excitation radiation to the object (condensation function) 
as well as the collection of the emitted fluorescence radiation. A Zeiss oil immersion lens (made 
of glass types of low autofluorescence) with 40 magnifications and a high numerical aperture 
(1.3) was used. It possesses high transmission in the near UV range (> 40 % at 340 nm) which 
makes it ideal for Fura loaded islets or cells.
As an imaging detector, a digital CCD (charge coupled devices) camera was used as the 
quantum yield of most fluorochromes is low. It captures the incoming photons of the 
fluorescence radiation and converts them into digital data (pixels). The camera can be adjusted 
to be synchronized with the changing excitation. The calculated cell fluorescence ratio (pixel-
per-pixel division) was then converted into adequate picture elements, which constitute the 
regions of interest (ROI's). The kinetics was then calculated by using a special computer 
program (Fucal, TILL Photonics).
3.5.3 Measurement of the cytosolic Ca2+ concentration in perifused pancreatic islets
3.5.3.1 Properties of the ratiometric fluorescent indicator Fura- 2 
The measurement of the free calcium concentration [Ca2+]i in the cytoplasm of living cells with 
calcium-sensitive fluorescent dyes is a well-established technique (Roe et al., 1990; Moreton, 
1994). Measurement of [Ca2+]i in the pancreatic islets was carried out with 2? procedures
(measure the fluorescence of a dye after excitation with two different excitation wavelengths). It 
offers the ratiometric fluorescence measurements to be made so that the ratio (R) of two 
fluorescence intensities (F340/ F380 X100) could be calculated. The fluorescence ratio is only 
dependent on the concentration of intracellular Ca2+ and independent of the indicator 
concentration. For 2? process, indicator dyes undergo a change in their excitation spectra to other 
wavelengths “shift" upon Ca2+ binding. Fura-2/AM is established as a fluorescent dye suitable 
for [Ca2+]i concentration (Grynkiewicz et al., 1985). For the measurements of [Ca
2+]i
concentration, the calcium sensitive dyes, must have the following properties: 
• Minimal interaction with the cellular processes.
• Good movement of the substances across the cell.
3. Materials and methods 33
• The possibility of non-invasive measurement of Ca2+-concentration 
• High selectivity of binding to the Ca2+-ions over other mono-and divalent ions. 
Compared to the previously developed Ca2+ indicators, Fura-2 has a higher quantum yield of 
fluorescence and higher molar extinction coefficients (the ability to absorb photons). Therefore,
a good signal-to-noise ratio (SNR) can be obtained at low probe concentration with much less 
disturbance of biological systems. Fura-2 exhibit Kd values that are close to typical basal Ca
2+
levels in mammalian cells (~100 nM). Nevertheless, Ca2+ binding is prominently perturbed by 
physiological levels of Mg2+; the Kd for Ca
2+ of Fura-2 is ~135 nM in Mg2+-free Ca2+ buffers 
and ~224 nM in the presence of 1 mM Mg2+ (Van den Bergh et al., 1995).
Esterification of the hydrophilic carboxyl group renders the dye cell permeable. Once within the 
cell, Fura- 2/AM (Acetoxy Methyl ester) is cleaved by the intracellular esterase enzymes freeing 
the negatively charged dye essentially trapping it within the cell where it is able to bind Ca2+
(Tsien, 1989). Sometimes AM ester hydrolysis is incomplete (Highsmith et al., 1986; Scanlon et 
al., 1987) or the fluorescence becomes compartmentalized within the organelles (Almers and 
Neher, 1985; Steinberg et al., 1987).
Fura-2 is a highly specific Ca2+ chelator and binding changes its fluorescent properties. In the 
presence of Ca2+, maximum Fura- 2 fluorescence (at 510 nm emission) is observed at wave 
length 340 nm and in Ca2+ free conditions at 380 nm as shown in Fig 3.4. Therefore, it follows 
that the concentration of free intracellular Ca2+ is proportional to the ratio of fluorescence at 
F340/F380. Ca
2+ binding shifts the excitation spectrum about 30 nm to shorter wavelengths, so that 
the ratio of intensities obtained from 340/380 nm or 350/385 nm excitation pairs is a good 
measure of [Ca2+]i; unperturbed by variable cell thickness or dye content (Fig 3.5). This "shift" 
is the reason that Fura-2 is one of the most common indicators for quantitative measurements of 
the [Ca2+]i concentration (Lambert, 1999). The Grynkiewicz equation describe this relationship
[Ca2+]i (nm) = Kd (R- R min) / (R max- R) Sfb
Where Kd is the Ca
2+-Fura-2 dissociation constant =225 nM, R= F340/F380 ratio, R max =
F340/F380 ratio under Ca
2+ saturating conditions, R min = 340/380 ratio under Ca
2+ free conditions, 
and Sfb = ratio of baseline fluorescence (380 nm) under Ca
2+ free and bound conditions.
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Figure 3.4 The Ca2+ dependent fluorescence excitation spectra of Fura-2 in solutions containing 
0–39.8 µM free Ca2+. Upon binding Ca2+, fura-2 exhibits an absorption shift that can be observed by 
scanning the excitation spectrum between 300 and 400 nm, while monitoring the emission at ~ 510 nm 
(Mammano and Bortolozzi, 2010).
3.5.3.2 Properties of the ratiometric fluorescent indicator Fura- PE3
One of the most common problems seen with Fura-2 is its tendency to both leak out of cells and 
accumulate in organelles (Di Virgilio et al., 1990; Goligorsky et al., 1986). It is known to be 
released from the cells either passively or by anion transport (Jakob et al., 1998; Manzini and 
Schild, 2003). This leads not only to a decrease in the fluorescence emission but also to 
distortion of the results since the released indicator will report the Ca2+ of the extracellular 
space. For this reason, Fura-PE3/AM was designed by Dr. Poeni group (Austin, Texas) in 1995 
to resist compartmentalization and leakage by virtue of an added positive charge containing a 
piperazine ring, the nitrogen with the adjacent carboxyl groups to form a Zwitterion (Vorndran 
et al., 1995). Fura-PE3 though shares the basic properties of Fura- 2, but with decreased rate of 
leakage which is estimated to be about 0.2 % per minute (Milner et al., 1998). This rate is slow 
enough for the cells to retain a useful amount of the indicator for several hours and makes it 
ideal for loading the islet cells (Vorndran et al., 1995). 
Fura 2AM Fura PE3
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The concentration of fluorescent dyes in the incubation medium should be adjusted so that a 
sufficient dye level must be attained to achieve an adequate SNR. However, it was important to 
avoid high levels that may cause Ca2+ buffering by the dye itself and to protect ? cells against the 
potentially toxic degradation products of hydrolysis (acetate and formaldehyde). On the other 
hand too low concentration will result in a very low fluorescence signal.
After cultivation period of 24-72 h, the pancreatic islets or islet cells were loaded just before the 
experiment. Certain criteria should be fulfilled in pancreatic islets, used for the experiments:
1. It had to be free from exocrine tissue
2. The pancreatic islets should be round and be enveloped by a thin capsule 
3. They should preferably have a small diameter as both the degree of electrical coupling 
and calcium are inversely related to the islet size (Gilon et al., 1994; Ravier et al., 2002).
The perifusion chamber was specifically designed so that it had a depression in the middle to be 
filled first with mKRB buffer. Laboratory vacuum grease (Glisseal®) was used as an adhesive 
and sealing compound on the cover glass. After loading the islet or islet cells attached to the 
cover slip with the respective indicator, it was placed to be firmly fixed in the middle the 
perifusion chamber in such a way that the solutions flowing around it, avoiding the possible 
entrance of air bubbles. With the help of the downstream peristaltic pump, an even flow through 
the system could be ensured (the flow speed of 200 ?l / min). After applying a drop of 
immersion oil (Leitz, Wetzlar) with low fluorescence, the islet or cells were focused in the 
transmitted light. To avoid any interference with the physiological functioning of the pancreatic 
islets, the temperature was kept at 36 °C during the experiments (Nadal et al., 1994). In addition, 
the perifusion solutions were heated using a water bath and the lens was wrapped with a current-
carrying resistor foil and thereby heated (not applied on single cells). The chamber and the 
objective were connected through the immersion oil to achieve a temperature of 36 °C in the 
perifusion chamber. The water bath containing the test solutions was adjusted at 44 - 46 °C and 
the resistance film on the lens was heated to 45-50 °C. When these conditions were fulfilled, the 
measured temperature in the perifusion chamber was ~ 36 °C. For the fluorescence 
measurement, the laboratory was kept dark in order to minimize measurement errors due to 
ambient light. After completion of the experiment the chamber as well as the tubes were cleaned 
with distilled water and dried.
Ratio images were obtained by acquiring pairs of images at alternate excitation wavelengths: 
one image for 340 nm and the other for 380 nm excitation wavelengths. The advantage of this 
system is that it enables to select images stored in the different regions (ROI's) to be compared
as shown in Fig 3.5. In addition, for data analysis and calculation of kinetics, the pancreatic islet 
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had been divided into 6 sections, a ROI in the centre, and the other ROI's were positioned 
peripherally in a clockwise direction (Ravier et al., 2002). For testing the functional integrity of 
the cultured pancreatic islets, they were exposed to 10 mM glucose to show the oscillations and 
their synchronicity throughout the islet (Fig 3.5).
3.5.3.3 Experimental procedure to achieve a net Fura fluorescence ratio in the presence of 
non- negligible interference
The measurements of [Ca2+]i concentration were rendered difficult by the autofluorescence of 
the fluoroquinolones which increased values of the Fura-fluorescence ratio (Gross Fura 
fluorescence ratio). Therefore, for each individual compound, a correction procedure was 
necessary. This was achieved by repeating each experiment with sham-loaded pancreatic islets 
or ? cells i.e. the islets or the islet cells were incubated with mKRB containing 5 mM glucose 
without Fura. The fluorescence trace excited at 340 nm and that excited at 380 nm were 
subtracted from the corresponding trace obtained with Fura-loaded islets or ? cells (Fig 3.6).
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Figure 3.5 Determination of [Ca2+]i concentration in the presence of Krebs-Ringer medium 
containing moderate stimulatory level of glucose (10 mM). A cultured pancreatic islet was loaded 
with Fura-2 AM. The islet show oscillatory pattern. Selected regions of interest (ROIs) are numbered 
beginning from the islet core (sub-region 1) then followed by the peripheries (sub-regions 2-7).
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Figure 3.6 Difference between the gross fluorescence of gatifloxacin and the Ca2+-dependent 
Fura-fluorescence ratio .The gross fluorescence represented by the grey line is the uncorrected ratio 
between the excitation wave lengths of 340 nm and 380 nm. The black line represents the net Fura 
fluorescence ratio after subtraction of the endogenous fluorescence of gatifloxacin at both wavelengths
i.e. the pancreatic islets as well as ? cells are incubated with Krebs Ringer medium containing 5 mM 
without Fura (Sham-loaded).
3.5.4 Measurement of NAD(P)H autofluorescence 
The characteristic autofluorescence of NADH (and also NADPH) enables a view on 
mitochondrial function and cellular energy metabolism (Chance and Baltscheffsky, 1958). The
term autofluorescence is used to distinguish it from the fluorescence of indicators that are 
artificially introduced. It is important to emphasize that these changes in signal do not indicate 
the net changes in the absolute size of the total pool but rather a change in the balance of 
reduced to oxidized form (Duchen et al., 2003).
The autofluorescence signal measured described in this protocol stems from both mitochondrial 
and cytosolic NADH and NADPH. As the autofluorescence spectra are identical (Fig 3.7), it is 
not possible to distinguish between the signals originating from these two; for this reason 
NAD(P)H, will be used to indicate that the signals are derived from either NADH or NADPH, 
or both (Schuchmann et al., 2001). Several factors suggest that the bulk of signal originates from 
the mitochondrial pool of NAD(P)H not only in pancreatic islets or ? cells but also in other cell 
type in which mitochondria represent a substantial proportion of the total cell volume (Patterson, 
et al., 2000). One of the properties that strengthen the mitochondrial component of the signal is 
that binding of NADH to membranes enhances the fluorescence, whereas enzymatic binding 
tends to quench the cytosolic fraction. An increase in the activity of Krebs cycle, through the 
Ca2+ dependent up-regulation of the enzymes or through increased delivery of substrate will 
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increase the balance in the favour of NAD(P)H (Mojet et al., 2001). For the determination of 
NAD(P)H concentration in the pancreatic islets, single wave length approach had been used. 
The excitation and emission spectra of NAD(P)H molecules are relatively broad (peak excitation 
in the near UV ~ 340-360 nm; emission in the blue range ~ 430–450 nm) as shown in Fig 3.7A.
High pressure mercury lamp (Heraeus-Hanau, ST41) was chosen as a light source for specific 
stimulation of NAD(P)H molecules. This mercury lamp emits light in the range between 360-
370 nm, i.e. in the area of the absorption maximum of the fluorophore sufficient for excitation of 
NAD(P)H molecules.
The Excitation light was directed using Leitz epifluorescence microscope which differs in some 
aspects compared to that used for calcium measurements.
1. A Uniblitz-shutter (Vincent, Rochester, USA) operated at a frequency of 1 Hz with an 
exposure time of 0.2 s, which close the light in order to avoid photobleaching. 
2. An Excitation filter: Band Pass 365 + 15 nm, WB 50 (Omega Optical, Brattleboro, VT).
3. Emission filter: 450 ± 32 nm (Omega Optical, Brattleboro, VT). 
4. The emission was separated by a dichroic mirror at 405 nm. 
5. The fluorescence was recorded by a photon-counting multiplier (Hamamatsu Photonics, 
Japan; H-3460-04). The resulting ECL pulses were transformed into TTL pulses, which 
could then be counted and displayed to the computer via a Counter/Timer Board (CTM-
05) (Plug-in electronic, Eichenau, Germany). The data acquisition program used was 
Labtec Notebook (Labtec Inc, Wilmington, Massachusetts, USA). The photomultiplier 
provides the possibility of detecting very low intensities with a high resolution.
For measurement of NAD(P)H autofluorescence, the islet (attached to the cover slip) was 
inserted in a purpose-made perifusion chamber on the stage of an epifluorescence microscope 
equipped with a mercury arc lamp and a temperature-controlled objective (Fluar 40x, 1.3 N.A., 
Carl Zeiss, Göttingen, Germany). 
3. Materials and methods 39
Figure 3.7 NAD(P)H excitation and emission spectra. Purified NADH and NADPH were suspended to 
1 ?M concentration in 50 mM Na2HPO4/50 mM sodium acetate/50 mM glycine, pH 7.0. The excitation 
spectrum was obtained by exciting at wavelengths from 300 nm to 460 nm while detecting emission at 
465 nm. The emission spectrum was obtained by exciting 340 nm and scanning the emission wavelength 
from 350 nm to 600 nm. NADPH spectra exactly overlay NADH spectra (Patterson et al, 2000).
3.5.5 Measurement of FAD autofluorescence
Another source of redox related autofluorescence comes from oxidized cellular flavoproteins
(Panten and Ishida, 1975; Chance et al., 1979). Like NAD(P)H, Flavin Adenine Dinucleotide
(FAD) show differential fluorescence between their oxidized and reduced states. In contrast to 
NAD(P)H, these molecules are fluorescent in their oxidized state as their electrons assume 
maximum resonance, becoming prone to brief excitation to a higher energy state by blue light, 
followed by reversion to lower energy orbitals with the emission of green light. FAD are excited 
with 440 ± 10 nm excitation, away from the maximum excitations of tryptophan (~ 300 nm) and 
porphoryins (~ 400 nm) (Wagnières et al., 1998). The emission separated by a dichroic mirror at 
455 nm and filtered by a 502 nm long pass filter (Omega Optical, Brattleboro, VT) (Fig 3.8). 
FAD molecules have the particular advantages of being spatially restricted to mitochondria, and 
thus being a direct measure of cellular metabolism (Husson et al., 2007).
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Figure 3.8 Fluorescence excitation and emission spectra of standard FAD. Excitation spectrum 
(broken line) was taken at 520 nm emission, emission spectrum (solid line) with excitation at 450 nm 
(Munro and Noble, 1999)
3.5.6 Measurements of the Rhodamine 123 fluorescence as a parameter of ??? in
perifused single pancreatic ? cells
One full turn of the Krebs cycle generates 3 NADH and one FADH2 molecules, which convey 
reducing equivalents to the respiratory chain. The increased supply of reducing equivalents is 
expected to increase the rate of electron transport which should increase the proton efflux from 
the matrix space. During the redox reactions, these protons are translocated across the inner 
mitochondrial membrane to the intermembrane space, generating an electrochemical proton 
gradient that is expressed largely as a membrane potential of the order of 150 - 200 mV (negative 
inside i.e. in the matrix space). This potential is referred to as “delta psi"(???) and provides the 
driving force for proton influx through the F1F0 - ATP synthase. Finally, ATP is generated and 
transported to the cytosol (Fig 3.9) (Mitchell and Moyle, 1967).
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Figure 3.9 Mitochondrial respiratory chains. It consists of four enzyme complexes (complexes I - IV) 
and two intermediary substrates (coenzyme Q and cytochrome c). The NADH+H+ and FADH2 produced 
by the intermediate metabolism are oxidized further by the mitochondrial respiratory chain to establish an 
electrochemical gradient of protons, which is finally used by the F1F0-ATP synthase (complex V) to 
produce ATP (modified from Bellance et al., 2009)
Rhodamine 123 (Rh123 as shown below) is a fluorescent lipophilic cationic dye known to be 
specifically partitioned into negatively charged mitochondrial membranes. It has an excitation 
spectrum with the maximum of 500 nm and a molar extinction coefficient of 7.5 x 104 M? 1
cm? 1 in water (Darzynkiewicz et a1., 1981). Previous studies using Rhodamine 123 to measure 
mitochondrial activity established that (??m) hyperpolarize in response to increased glucose 
concentration in ? cells leading to redistribution within the cell. The increased mitochondrial 
Rh123 uptake and concentration lead to self-quenching of fluorescence within the mitochondria
and to a decrease of the total signal (Nunemaker et al., 2004; Kindmark et al., 2001; Krippeit-
Drews et al., 2000). In response to mitochondrial depolarization, the dye will leave mitochondria 
and move into the cytosol resulting in an increase of the total fluorescence signal. Mitochondrial 
poisons (uncouple respiration from phosphorylation) that dissipate the mitochondrial membrane 
potential, such as CCCP increase Rh123 fluorescence by preventing its uptake (Rustenbeck et 
al., 1997a; Anello et al., 2005). Similarly, electron transport inhibitors such as azides (e.g. NaN3)
eliminate Rh123 uptake.
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For m???????????? ??? ???m), pancreatic ? cells attached to the cover slip were loaded by 10 
??????of Rh123 for 10-15 min at 37??C. Thereafter, the cells were washed and transferred to the 
perifusion chamber. The set up of epifluorescence microscope is similar to that used for calcium 
measurements except some features that were changed to fulfil the fluorescence characters of 
Rh123 being excited at 490 nm and its emission was collected at 535 nm. Excitation was 
performed by xenon lamp at 495 nm using an excitation filter (BP 450–490 nm). The emitted 
fluorescence was passed through a 500-nm long-pass dichroic mirror and a 535/25 nm band-pass 
filter (filter block I3, Leica).
3.6 Measurement of the adenine nucleotide content in pancreatic islets 
3.6.1 Principle of ATP/ADP measurement 
ATP is detectable in all metabolically active cells and its concentration decreases rapidly when 
cells lose their vitality and die (Kangas et al., 1984). At present, there are no direct fluorescent 
indicators for ATP or ADP. Rather, ATP is measured by a luminescence reaction where the
emitted light is proportional to the ATP concentration (Mojet et al., 2001).
The determination of ATP and ADP content in the isolated mouse pancreatic islets was done by 
a modification of the procedure used by Detimary et al. (1996). For the measurement of ATP, a 
bioluminescence kit of Sigma was used. When light emission was initiated by the addition of 
luciferase into a reaction mixture containing Mg2+ (or another divalent cation such as Mn2+), and 
luciferin (4,5-dihydro-2-6-hydroxy-2-benzothiazolyl thiazole-4-carboxylic acid), where all 
components are near or at saturating concentrations, the luminescence observed is proportional 
to the ATP content in the samples. The ADP content was indirectly determined by prior 
conversion of ADP to ATP by pyruvate kinase (PK) reaction. The latter catalyzes the formation 
of ATP and pyruvate from ADP and phosphoenol pyruvate. Seliger and McElroy (1960)
describe the reaction as follows: 
Mg
2+
Pyruvate kinase
Pyruvic acid
ATP ADP
Phosphophenol pyruvate
Luciferin + ATP Luciferyl-AMP+ PPi
Luciferase
Luciferyl-AMP+O2 Oxyluciferin + AMP + CO2 + Light
Luciferase
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The transition of the Oxyluciferin is associated with light emission of the wave length 562 – 560 
nm (green yellow light) which is directly proportional to the ATP concentration. Because the 
quantum yield of this bioluminescence reaction is 0.88, almost one photon is emitted per 
reaction cycle. The multiple photon counter used to measure ATP luminescence, can detect even 
single photons with high sensitivity.
3.6.2 Incubation and sample preparation
The sample and control were incubated simultaneously. To prepare the incubation, 10- ml
Eppendorf tubes were filled with 1.5 ml distilled water had been saturated with Carbogen for 5 
minutes in a water bath at 37 °C. Then 15 freshly isolated pancreatic islets were transferred in 50
?l mKRB into 1.5 ml Eppendorf tube containing 450 ?l test solution. The Eppendorf tube
containing the islets was placed inside the 10 ml Falcon tube and this assembly was again placed 
under a stream of Carbogen for about 5 minutes. Thereafter, the outer tube was tightly closed and 
was placed in a shaking water bath (shaking position 7, Kötterman) at 37 °C. The incubation 
conditions were made to mimic the experimental protocol used with the reducing equivalents. 
After 60 minutes pre-incubation under the above conditions, the test agents (glucose or 
fluoroquinolones) were added in a volume of 500 ?l (pre-warmed and equilibrated with 
Carbogen) , resulting in a total incubation volume of 1000 ?l. After a short vortex-mixing, the 
incubation was continued for the specified time. At the end of incubation time, the Eppendorf
tubes were removed and placed on ice. 800 ?l of the incubation volume was removed and 100 ?l 
of ice-cold 15 % trichloroacetic acid (TCA) was added to the remaining volume of 200 ?l
containing the islets to precipitate the proteins. After vortex mixing for 1 minute, the cups were 
placed on ice and the proteins were sedimented by centrifugation (10.000 g at 4 °C for 3 
minutes). To eliminate TCA from the supernatant, 240 ?l of supernatant was mixed with 900 ?l 
of water- saturated diethyl ether in Eppendorf tube, and the ether phase containing TCA was 
removed and discarded. This procedure was repeated 3 times to ensure complete removal of 
TCA. Thereafter, the samples were mixed with 240 ?l neutralization buffer (20 mM HEPES + 3 
mM MgCl2 were dissolved in water), the pH of which was adjusted to 7.75 with 1N KOH. After 
this treatment, the samples could be stored at -18 °C or processed further.
3.6.3 ATP/ADP measurement
For the measurements of ATP content, 50 ?? (from a total volume of 480 ??) was added to 300 ??
dilution buffer. 100 ?? of this mixture was pipetted into a 96-well plate. The micro-well plate was 
inserted into the luminometer (Victor2 multilabel counter, Wallace, PerkinElmer) and the 
following steps were done automatically by the measurement program of the luminometer. 100 
?? assay mix (dissolved 1:50 with dilution buffer) was injected into the well in the measurement 
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position. After shaking and a delay time of 10 s, the resulting luminescence was measured with a 
photon counting multiplier. The raw data was thus expressed as counts per second.
The measurement of ADP required the previous conversion of the ADP to ATP. To this end, 50 
?? (from the above mentioned 480 ?? sample) was mixed with 300 ?? dilution buffer, containing
additionally phosphoenol pyruvate (1.5 mM, Boehringer) and pyruvate kinase (2.3U/ml,
Boehringer). After incubation for 45 min at 37 °C, 100 ?? of this mixture was pipetted into a 96-
well plate and measured as described for the ATP content.
3.6.4 Preparation of the ATP and ADP standard curves
The lyophilized powder of the assay mix (ATP bioluminescence kit, Sigma) was dissolved in 5 
ml distilled water and stored in aliquots at - 20 °C. For the experiments the assay mixture was 
diluted in the ratio 1: 35 with assay mix dilution buffer (also contained in the sigma kit). Based 
on the concentration of 2x10-7 pmol ATP, the stock solutions were diluted so that the resulting 
standard curve comprised values from of 0-10 pmol ATP. The dilution was done with sterilized 
ultrapure water. For the luciferase reaction, ???????????? standard dilution were mixed again with 
???????of mKRB plus dilution buffer. The composition of the resulting mixture mimics exactly 
the mixture of the biological samples plus reaction buffer. 100 ?? were transferred per well of the 
microliter plate.
The various dilutions of ADP standard curve were first incubated for 45 minutes at 37 °C to 
achieve an enzymatic conversion of the ADP to ATP. To this end, 5 ?l of each standard dilution 
was first diluted to 50 ?l and then treated in the same way as described above for the biological 
samples.
3.6.5 Luminescence measurement and data analysis
For better precision, the average values of two measurements were calculated. Both ATP and 
ADP standard curves could be fitted with a linear function, which permits the use of linear 
regression to calculate the adenine nucleotide content from the luminometric signal. The ADP-
content was calculated as the difference between the ATP in a sample and the ATP content after 
enzymatic conversion, which corresponds to the sum of ATP plus ADP. Thus the final result of 
this measuring procedure is the ATP and ADP content per islet. For a more sensitive detection of 
significant differences, the calculated ATP- to ADP- ratios were normalized to 100 % for each 
single control experiment. 
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3.7 Electron microscopic examination
The pancreatic islets were extracted as described in 3.4.1.2. Batches of 50 islets were pooled and 
cultured with RPMI medium using two different concentrations for each of the 3 drugs; 10 and 
100 ?M and without addition of penicillin/ streptomycin to avoid any possible interaction. After 
tissue culture for 20 hours, the islets were fixed for electron microscopy (Jörns et al., 1997) by 
immersion in a solution containing para-formaldehyde (2%) and di-glutaraldehyde (2%) in 
cacodylate buffer (0.1 M, pH 7.3). The tissue was post-fixed in 1% osmium tetroxide (OsO4) for 
1 h and embedded in epoxy resin. Thin sections of the islet pellets were cut at 50 nm with an 
ultramicrotome (Ultracut, Reichert-Jung, Nussloch, Germany), placed on nickel grids and 
contrast-stained with uranyl acetate and lead citrate. The thin sections were viewed in an electron 
microscope EM 9 (Zeiss, Germany). In initial qualitative studies, 10–15 islets of different sizes 
in each pellet were examined. Exocrine parenchymal cells and ?, ?, ? were identified on the basis 
of their morphology and the incidence of degenerative changes induced by the test compounds in 
each of the cell types was observed.
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4. Results
4.1 Effect of fluoroquinolones on [Ca2+]i
[Ca2+]i concentration of pancreatic islets was analyzed in order to gain insight into the 
insulinotropic effect of the fluoroquinolones. Changes in [Ca2+]i were measured in pancreatic 
islets as well as ? cells of female NMRI mice using the fluoroprobe Fura-PE3 and Fura-2/AM, 
respectively. The results of the ratiometric Fura-2 based fluorescence measurements presented 
for each fluoroquinolone. The uncorrected data was defined as Fura- Gross fluorescence ratio, 
while the corrected Ca2+ - dependent fluorescence signals was corresponding to the net Fura 
fluorescence ratio. As each of the three used compounds had its own endogenous emission 
fluorescence and the corresponding ratio, the dissociation between the fluoroquinolone-specific 
autofluorescence and Ca2+- dependent Fura fluorescence ratio was based on the principles 
outlined in Chapter 3.5.3.3.
The functional integrity of the cultured ? cells together with pancreatic islets was tested by 
exposure to a maximum depolarizing K+ concentration (40 mM). This stimulus evoked increase 
in [Ca2+]i regardless of the glucose concentration (Gilon and Henquin, 1992; Rustenbeck, 1999). 
At the same time, the extent of K+-induced depolarization was used as an internal standard for 
the assessment of [Ca2+]i -modulating potency of the tested fluoroquinolones. The control phase 
was carried out initially from minute 10 - 20 prior to the actual exposure of the respective test 
drug. In the view of  the variability among individual islets/ ? cells, six islets from two different 
NMRI albino mice was used for the calculation of mean ± SEM of Fura fluorescence ratio.
During the first 10 minutes, Ca2+ signal profile was initially recorded, with two different glucose 
concentrations; basal glucose concentration (5 mM) and a moderately effective glucose stimulus 
(10 mM). 
4.1.1 Glucose-dependence effect of fluoroquinolone induced [Ca2+]i changes
The effect of ???????gatifloxacin on the [Ca2+]i was assessed in the presence of basal glucose. 
The stimulation of cultured islets with an exogenous K+ concentration (40 mM) over a period of 
10 minutes caused an immediate increase in the Fura fluorescence ratio. The maximum level of 
depolarization (minute 13) corresponded to a fluorescence ratio of 86 units. This was followed 
by a plateau phase. Restoration of the fluorescence ratio nearly to the basal level (54 units) 
occurred when K+ was washed out. Exposure of the islets to gatifloxacin from minute 30- 50 did 
not produce any significant increase in the net ratio compared to the pre-stimulatory ratio. 
Perifusion of the islets with KCl together with gatifloxacin from minute 50-60 was still capable 
of inducing the characteristic increase in the ratio to 67 units; though not to the same extent as 
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the first exposure to KCl, but still effective (Fig 4.1A). An alternative protocol was used in 
which the perifusion with gatifloxacin from minute 10 - 40 could not produce any significant 
increase in the net ratio. When perifused with KCl from minute 60 - 70, the islets responded well 
and the ratio was increased from 24 to 41 units (Fig 4.1B).
??? ??????????????????? ???? ??????????????????????????????????????????????? ??????????????? - 30, 
followed by increase to 500 µM from minute 30 - 50. As shown before, gatifloxacin did not 
cause a significant increase in [Ca2+]i ?????????????????????????????????????????t increase by 
28 units. Gatifloxacin washout resulted in immediate re-establishment of the fluorescence ratio 
even to a level below pre-stimulatory values then returned rapidly to reach a steady state. The 
use of D-600 from minute 70 - 90 slightly reduced the ratio (Fig 4.2).
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Figure 4.1 Effect of gatifloxacin on [Ca2+]i in the presence of a basal glucose concentration in 
NMRI mouse islets. A) Pancreatic islets have been incubated for a period of 45 minutes with Fura-2. 
During the entire experimental period of 90 minutes a Krebs-Ringer medium with basal glucose 
concentration of 5 mM was used. The functional integrity of the islets was tested from minute 10-20 by 
the characteristic response to a maximum K+-depolarizing stimulus. The islets were then exposed to 
gatifloxacin 100 ?M from minute 30-50 where no increase in [Ca2+]i was observed. The islets were even 
still responsive to KCl in the presence of gatifloxacin. B) The islets were first exposed to gatifloxacin from 
minute 10-40, again show no influence on the [Ca2+]i. The islets still respond to KCl after pre-exposure to 
gatifloxacin.
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Figure 4.2 Effect of two different concentrations of gatifloxacin on [Ca2+]i in the presence of a 
basal glucose concentration in NMRI mouse islets.. Cultured normal mouse ? cells were perifused 
with Krebs-Ringer medium containing 5 mM glucose. From minute 10-30, the medium contained 100 ???
gatifloxacin and then increased to 500 ????????minute 30-50. After wash-out the basal value of the net 
Fura fluorescence was established by 50 ??? ?????? ??????? ???? ????? ± S.E.M of 26 loaded and 30 
sham-loaded ? cells from 4 experiments each.
???? ??????? ??? ???? ??? ????????????? ???? ????? ????????? ??? the presence of 10 mM glucose 
concentration. Perifusion with gatifloxacin from minute 40 - 70 induced a pronounced increase 
in [Ca2+]i with latency of 2 minutes, and then a steady state was reached till the end of perifusion 
(Fig 4.3A). The magnitude of the effect was higher than that of a preceding KCl depolarization. 
The dependence of Ca2+ influx through calcium channels as a result of closure of the KATP
channels was also analyzed. This was done by using diazoxide and D-600, respectively. First, 
gatifloxacin caused increase in [Ca2+]i after a 3 minutes latency period to reach a steady state of
39 units. Then, 300 µM diazoxide from minute 50 - 70, caused a partial reduction of 
??????????????????? ?????????????? ??????????????????????????????????????-600 reduced the mean 
values somewhat, but did not re-establish the pre-stimulatory values. The typical effective 
increase in Fura fluorescence ratio produced by KCl depolarization was from 25 to 37 units. 
Stoppage of KCl perifusion (at minute 20) reduced the fluorescence ratio to pre-stimulatory 
values (Fig 4.3B).
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Figure 4.3 Effect of gatifloxacin on [Ca2+]i in the presence of 10 mM glucose in NMRI mouse islets. 
A) The functional integrity of the islets was tested from minute 10- 20 by the characteristic response to a 
maximum K+-depolarizing stimulus. Perifusion with 100 uM gatifloxacin was performed from minute 30-
90. B) 300 ?M diazoxide (KATP channel opener) was added from minute 50-70.Additionally, 50 ?M of D-
600.The [Ca2+]i was increased to level even exceeding K
+ depolarization. However, it is decreased by 
diazoxide, even further reduction was observed by addition of D-600, although, in both, [Ca2+]i did not 
return to initial values. Data represent means ± SEM based on the analysis of 3 pancreatic islets, for 
each.
The exposure of cultured islets to 100 µM moxifloxacin in the presence of glucose (5 mM) 
resulted in an increase in the net Fura fluorescence ratio by 17 units after 2 minutes. The ratio 
was further increased by 20 units when moxifloxacin concentration was increased to 500 µM. 
Washout of moxifloxacin led to a clear decrease of the fluorescence ratio to the level prior to 
exposure to 500 µM. The use of D-600 from minute 70 failed to further reduce the ratio (Fig 
4.4). Testing the effect of 100 µM moxifloxacin in the presence of 10 mM glucose showed an 
increased Ca2+ concentration compared with the plateau phase of K+-induced depolarization. 
Regarding the kinetics of [Ca2+]i , the ratio was increased after a latency of one minute and 
reached to a steady state within two minutes (Fig 4.5). In a direct comparison with gatifloxacin 
(Fig 4.6), moxifloxacin was rather less efficient (increase by about 20 instead of about 27 ratio 
units); again the effect was of a remarkable fast onset.
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Figure 4.4 Effect of moxifloxacin on [Ca2+]i in the presence of a basal glucose concentration in 
NMRI mouse ?? ?????. Cultured normal mouse ? cells were perifused with Krebs-Ringer medium 
containing 5 mM glucose. From minute 10-30, the medium contained 100 ???moxifloxacin and then 
increased to 500 ????????minute 30-50. After wash-out the basal value of the net Fura fluorescence was 
established by 50 ????????????????????????? ± S.E.M of 24 loaded and 29 sham-loaded ? cells from 4 
experiments each.
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Figure 4.5 Effect of moxifloxacin on [Ca2+]i in the presence of 10 mM glucose in NMRI mouse 
islets. The functional integrity of the islets was tested from minute 10-20 by the characteristic response 
to a maximum K+-depolarizing stimulus. Perifusion with 100 uM moxifloxacin was performed from minute 
30-50 and then washout for 20 minutes. Data represent means ± SEM based on the analysis of 3
pancreatic islets, for each.
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Figure 4.6 Comparison between the effect of gatifloxacin and moxifloxacin on [Ca2+]i in NMRI
mouse islets. Both gatifloxacin and moxifloxacin were used at a concentration of 100 uM in the 
presence of Krebs Ringer medium containing 10 mM glucose. Gatifloxacin 100 uM was added from 
minute 10-30, the washed out for 20 minutes before the islets perifused with moxifloxacin 100 uM. Data 
represent means ± SEM based on the analysis of 3 pancreatic islets, for each.
In the presence of basal glucose concentration, 100 ??? ?????????????? ???? ???? ???????? ???
increasing the fluorescence ratio. When the concentration was increased to 500 ?M the ratio 
increased by 20 units within 5 minutes. The washout period showed a partial reversibility with a 
delayed onset. Then, 50 µM D-600 added from minute 60 produced no further decrease (Fig 
4.7). The presence of D-600 in the perifusion medium from the beginning reduced the increment 
?????????????????????????????????????????????????????????????????????????????????????????????????
of  the washout (Fig 4.8).  For this reason, the protocol was repeated omitting Ca2+ from the 
perifusion medium. Essentially the same pattern was observed (Fig 4.9A). For comparative 
purpose, ???????????????????????????????????????????????????????4.9B). It increased the ratio 
values by nearly 20 units under normal conditions, but was totally ineffective in the absence of 
Ca2+ in the perifusion medium. 
?????? ???? ??????? ??? ???? ???? ???? ??? ?????????????? ??? ???? ????????? ??? ??? ??? ????????
was examined. After a lag time of about 15 minutes, a moderate increase by 5 units 
became visible. The values were further increased by 20 units when the concentration 
was increased to 500 µM. Washout (from minute 50 on) promptly but incompletely 
reduced the Fura ratio. The addition of D-600 from minute 70-90 (Fig 4.10) was not 
able to further reduce the ratio.
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Figure 4.7 Effect of ciprofloxacin on [Ca2+]i in the presence of a basal glucose concentration in 
NMRI mouse islets. Cultured normal mouse islets were perifused with Krebs-Ringer medium containing 
5 mM glucose. Ciprofloxacin conc. was changed from 100 ???(min. 10-30) to 500 ???from min. 30 to 50. 
The level of [Ca2+]i is still unexpectedly high even after wash-out continued for 30 minutes. Values 
represent means ± SEM based on the analysis of 3 pancreatic islets, for each.
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Figure 4.8 Effect of two concentrations of ciprofloxacin on [Ca2+]i in the presence of a basal 
glucose concentration in the presence and absence of D-600 in NMRI mouse islets. Cultured 
normal mouse islets or ? cells were perifused with Krebs-Ringer medium containing 5 mM glucose. 
Ciprofloxacin conc. was changed from 100 ??? (min. 10-30) 500 ??? from min. 30 to 50. The level of 
[Ca2+]i is reduced by the addition of D-600, however not return to the level prior to ciprofloxacin addition 
to the perifusion medium. Values represent means ± SEM based on the analysis of 3 pancreatic islets, 
for each.
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Figure 4.9 Effect of two concentrations of ciprofloxacin on [Ca2+]i in the presence of a basal 
glucose concentration in the presence and absence of Ca2+ in NMRI mouse islets. A) The effect of 
ciprofloxacin on the [Ca2+]i in the presence of a basal glucose concentration in a calcium free  Krebs-
Ringer medium compared to the effect of tolbutamide 500 ????Ciprofloxacin conc. was changed from 
100 ???(min. 10-30) to 500 ???from min. 30-50. The level of [Ca2+]i is not markedly different by absence 
of calcium from the medium. B) The effect of tolbutamide 500 ?? was completely abolished when the 
islets perifused with calcium free medium. Values represent means ± SEM based on the analysis of 3
pancreatic islets, for each.
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Figure 4.10 Effect of two concentrations of ciprofloxacin on [Ca2+]i in the presence of 10 mM 
glucose in NMRI mouse islets. Effect of ciprofloxacin on the [Ca2+]i in the presence of 10 mM glucose.
Cultured normal ? cells were perifused with Krebs-Ringer medium containing 10 mM glucose. 
Ciprofloxacin conc. was changed from 100 ???(min. 10-30) 500 ???from min. 30 to 50. [Ca2+]i is not so 
much increased using 100 ?? while only increased markedly at 500 ??. D-600 was ineffective to reduce 
the net ratio values considerably. Values are means ± S.E.M of 24 loaded and 20 sham-loaded ? cells 
from 4 experiments each.
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4.1.2 KATP channel-independent effect of fluoroquinolones on the [Ca
2+]i
The question whether the KATP channel blockade is indispensible for the [Ca
2+]i
increase was investigated by measuring the effect of gatifloxacin, moxifloxacin, and 
ciprofloxacin on SUR1 KO islets. The microfluorometric measurements of [Ca2+]i
from KATP channel-deficient SUR1 KO islets were carried out under the same 
experimental conditions as used for the normal NMRI islets. The net Fura fluorescence 
ratio was calculated as outlined before. Compared to islets from NMRI mice, the 
fluorescence ratio showed higher ratio values before the addition of the test 
compounds. In all experiments, the islets were perifused with mKRB containing 10 
mM glucose.
The SUR1 KO islets showed a modest (non typical) response to a high K+
concentration. The ratio was increased only from 53 to 64 units. In contrast, 100 µM 
gatifloxacin induced a marked increase of the Fura-fluorescence ratio (minute 30-50). 
After a transient reduction, it increased progressively and reached a steady state at the 
end of 20 minutes perfusion. 50 µM D-600 seemed to be ineffective in reducing the 
ratio. When gatifloxacin was withdrawn from the medium (minute 60), a prompt and 
massive reduction occurred (Fig 4.11).
The perifusion with 100 µM moxifloxacin (from minute 30-50) in the presence of 10 
mM glucose resulted in an instant increase in the net Fura fluorescence ratio from 58 
to 72 units. The use of D-600 from minute 50-60 failed to significantly reduce the 
ratio. However from minute 60-70, the washout in the presence of D-600 decreased the 
value to 63 units; though not to pre-exposure level. As in the preceding experiments 
with SUR1 KO islets, a strong KCl depolarization from minute 10-20 showed only a 
moderate increase in the fluorescence ratio by about10 units (Fig 4.12).
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Figure 4.11 Effect of gatifloxacin on the [Ca2+]i in the presence of 10 mM glucose in SUR1KO
islets. The functional integrity of the islets was tested from minute 10- 20 by the characteristic response 
to a maximum K+-depolarizing. Gatifloxacin 100 ???added from minute 30 to 60 interrupted by 50 ?? of 
D-600 from minute 50-60. Values are means ± S.E.M from a total of 3 pancreatic islets Fura loaded and 
3 sham loaded islets.
0 10 20 30 40 50 60 70 80
40
50
60
70
80
90
100
10 mM glucose
KCl 100 µM Moxifloxacin
50 µM D600
T im e (m in)
N
e
t 
F
u
ra
 F
lu
o
re
s
c
e
n
c
e
 r
a
ti
o
(F
3
4
0
/ 
F 3
8
0 
X
 1
0
0
)
Figure 4.12 Effect of moxifloxacin on the [Ca2+]i in the presence of 10 mM glucose in SUR1KO
islets. The functional integrity of the islets was tested from minute 10- 20 by the characteristic response 
to a maximum K+-depolarizing. Perfusion with moxifloxacin ?????? from minute 30-60 interrupted by 50 ?? of D-600 from minute 50-60. Values are means ± S.E.M from a total of 3 pancreatic islets Fura 
loaded and 3 sham loaded islets.
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Perifusion with 100 µM ciprofloxacin from minute 30-50 induced a moderate increase 
in the net Fura-fluorescence ratio from 60 to 81 units with a rapid initial and a 
protracted second response phase.  The effect of D-600 from minute 50-60 minutes 
resulted in a marginal reduction of 5 units. The washout in the presence of D-600 
resulted in a level that was close to pre-stimulatory conditions (minute 60-70). After 
completion of perifusion with D-600, the course of fluorescence ratio did not change 
(Fig 4.13).
The magnitude of this increase in [Ca2+]i caused by fluoroquinolones in SUR1 KO 
mouse islets was gatifloxacin > moxifloxacin > ciprofloxacin. Reversibility was 
observed with both gatifloxacin and ciprofloxacin but not with moxifloxacin.
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Figure 4.13 Effect of ciprofloxacin on the [Ca2+]i in the presence of 10 mM glucose in SUR1 KO
islets. The functional integrity of the islets was tested from minute 10- 20 by the characteristic response 
to a maximum K+-depolarizing. Perfusion with ciprofloxacin ?????? from minute 30-60 interrupted by 50 ?? of D-600 from minute 50-60. Values are means ± S.E.M from a total of 3 pancreatic islets Fura 
loaded and 3 sham loaded islets.
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4.2 Effect of fluoroquinolones on the autofluorescence of reducing equivalents 
4.2.1 NAD(P)H autofluorescence measurement in NMRI mouse islets
An increase in glucose concentration to 20 mM resulted in an increase in signal 
intensity by 35 ± 5 % within 300 s and subsequently returned to the prestimulatory 
after a latency of 100 s after glucose had been removed from the medium.  For more 
accurate comparison of the response to 20 mM glucose, the islets were also perifused 
with mKRB without glucose for 60 minutes where the intensity continued to decline to 
reach 90 % at 2400 s and 85 % at the end of perifusion. The raw data for NAD(P)H 
fluorescence (in arbitrary units) was presented (Fig 4.14A). However, variability in the 
size of pancreatic islets as well as the size of the illuminated area made the intensities 
quite variable, and so the resulting scatters of the mean values rendered a 
demonstration of significant drug effects difficult. For these reasons, the values were 
normalized to 100 % with respect to the last prestimulatory value i.e. before the 
change of glucose concentration to 20 mM. The increase at the end of perifusion with 
20 mM glucose in NMRI islets was 45 % relative to the control islets (Fig 4.14B).
To confirm that the signal of NAD(P) H fluorescence is mitochondrial in origin, CCCP 
was used which blocked the electron transport chain leading to maximal reduction of  
all components of the chain, including NAD(P)H. For this reason, 5 µM CCCP was 
added in presence of 20 mM glucose, where it reduced gradually the fluorescence to 
the level prior to exposure to CCCP by the end of 20 min perifusion (Fig 4.15). 
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Figure 4.14 Changes in NAD(P)H signal in response to 20 mM glucose in NMRI mouse islets at 36 
°C. A) Increase in NAD(P)H fluorescence intensity in pancreatic islets of the NMRI mouse by glucose at 
36 ° C. The islets were first perifused with Krebs-Ringer medium, containing the 0 mM glucose for 20 
minutes (second 0 to 1200). This was followed by an increase in the glucose concentration to 20 mM 
(second from 1200 to 2400) and from 2400 seconds till the end again lowering the glucose concentration 
to 0 mM. The signal intensity (arbitrary units) is plotted against time in seconds. The grey line shows the 
effect of perifusion of the islets with Krebs-Ringer solution 0 mM glucose. Values are means ± SEM of six 
experiments for each. Pancreatic islets were obtained from 2 different preparations. B) The same 
protocol but the values are normalized by setting the last pre-stimulatory value (20 min) to 100%.
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Figure 4.15 Changes in NAD(P)H signal in response to 20 mM glucose with CCCP in NMRI mouse 
islets at 36 °C. Effect of CCCP on the increased NAD(P)H fluorescence intensity brought about by 20 
mM glucose in pancreatic islets of the NMRI mouse. The islets were first perifused with Krebs-Ringer 
medium, containing the 0 mM glucose for 20 minutes (second 0 to 1200). This was followed by an 
increase in the glucose concentration to 20 mM (second from 1200 to 2400) and from 2400 seconds 
CCCP 5 ?M for the last 20 minutes of perifusion. Values are normalized by setting the last pre-
stimulatory value (20 min) to 100%. Values are means ± SEM of 3 experiments.
The following set of experiments, was performed to assess the influence of 
gatifloxacin, moxifloxacin, and ciprofloxacin (100 µM each) on NAD(P)H 
autofluorescence in response to glucose stimulation. The autofluorescence of each 
compound was measured both in the presence of 20 mM glucose and of 0 mM 
glucose.
???? ????????? ??? ????????????? ????? ?M) in the presence of 20 mM glucose increased the 
signal intensity 4 times after a latency of 120 s before reaching a steady state at 4800 
second. When 0 mM glucose was used from the start of perifusion, gatifloxacin still
elevated the intensity with the effect size and lag time similar to that seen when 20 
mM glucose was used (Fig 4.16A). When the glucose concentration was increased to 
20 mM the signal intensity of NAD(P)H increased to 45 % of the pre-stimulatory 
values (Fig 4.16B).
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Figure 4.16 Changes in NAD(P)H signal in response to gatifloxacin in the presence of 20 mM 
glucose in NMRI mouse islets at 36 °C. A) The islets were perifused with KR-medium contained 0 mM 
glucose (Second 0-600). In the second 1200 (minute 10-30), glucose concentration increased to 20 mM. 
Then, 100 ?M gatifloxacin was added from minute 30 for one hour (5400 second). B) The same protocol 
but the values are normalized by setting the last pre-stimulatory value (10 min) to 100%. The figure 
shows the islets response to increase glucose concentration prior to application of gatifloxacin. The islets 
were obtained from 2 different preparations. The grey line shows the effect of perifusion of the islets with 
only Krebs-Ringer solution without glucose then, gatifloxacin was added from minute 30 till the end of 
perifusion.
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The same protocol was applied to moxifloxacin where it increased the signal intensity 
about 20 times after a latency of 190 s (slower kinetics than gatifloxacin). A steady 
state had been reached only before termination of perifusion by 20 minutes. When 0 
mM glucose was used from the beginning of perifusion, still moxifloxacin elevated the 
intensity 25 times with a lag time of 80 s faster than that seen when 20 mM glucose 
was used (Fig 4.17A). Increasing glucose concentration resulted in increase of the 
signal intensity of NAD(P)H by 50% of the prestimulatory values (Fig 4.17B).
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Fig 4.17 Changes in NAD(P)H signal in response to moxifloxacin in the presence of 20 mM 
glucose in NMRI mouse islets at 36 °C. A) The islets were perifused with KR-medium contained 0 mM 
glucose (Second 0-600). In the second 1200 (minute 10-30), glucose concentration increased to 20 mM. 
Then, 100 ?M moxifloxacin was added from minute 30 for one hour (5400 second). (B) The same 
protocol but the values are normalized by setting the last pre-stimulatory value (10 min) to 100%. The 
figure shows the islets response to increase glucose concentration prior to application of moxifloxacin.
The islets were obtained from two different preparations. The grey line shows the effect of perifusion of 
the islets with only Krebs-Ringer solution without glucose then, moxifloxacin was added from minute 30 
till the end of perifusion.
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When ciprofloxacin was added in presence of 20 mM glucose for one hour, the 
fluorescence was doubled after 150 s without reaching a steady state till the end of 
perifusion. Using 0 mM glucose, ciprofloxacin also doubled the signal intensity (Fig 
4.18A). The perifusion with 20 mM glucose after 10 minutes increased NAD(P)H 
autofluorescence by 30-45% (Fig 4.18B).
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Figure 4.18 Changes in NAD(P)H signal in response to ciprofloxacin in the presence of 20 mM 
glucose in NMRI mouse islets at 36 °C. A) The islets were perifused with KR-medium contained 0 mM 
glucose (Second 0-600). In the second 1200 (minute 10-30), glucose concentration increased to 20 mM. 
Then, 100 ?M ciprofloxacin was added from minute 30 for one hour (5400 second). (B) The same 
protocol but the values are normalized by setting the last pre-stimulatory value (10 min) to 100%. The 
figure shows the islets response to increase glucose concentration prior to application of ciprofloxacin.
The islets were obtained from two different preparations. The grey line shows the effect of perifusion of 
the islets with only Krebs-Ringer solution without glucose then, ciprofloxacin was added from minute 30 
till the end of perifusion.
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4.2.2 Comparison between fluoroquinolones regarding NAD (P) H autofluorescence 
The pattern of NADH increase caused by each drug was quite different. When the 
values of NAD(P)H signal intensity were normalized at 1800 seconds ,the extents of 
increase caused by ciprofloxacin, gatifloxacin and moxifloxacin were 200 %, 125 %, 
and 138 % respectively. Ciprofloxacin had the least initial fluorescence intensity, 
gradually increasing without reaching a steady state. Whereas moxifloxacin initially 
showed extremely high values with very slow kinetic profile only assuming a steady 
state after 40 minutes of perifusion. Gatifloxacin kinetic profile started like 
ciprofloxacin concerning the initial fluorescence but differently reaching a steady state. 
To distinguish whether the largely different signal intensities were due a different 
accumulation of the compounds in the islet cells or to different fluorescence intensity 
in the NAD(P)H emission range, the fluorescence intensities of the 3 compounds was 
measured in the absence of islets but otherwise exactly the same experimental 
conditions (Fig 20). At an equimolar concentration moxifloxacin had a 25 fold and 
gatifloxacin 5.4 fold higher fluorescence intensity compared to ciprofloxacin. 
Corrected for these values the rank order of accumulation was cipro > gati > moxi. 
However, moxifloxacin showed the most marked increase of accumulation in the 
presence of 20 mM glucose (40.2% vs. 17.6% for both gati- and ciprofloxacin).  The 
time required for NAD(P)H to reach to half its peak value for each drug was 
compared. While the half-maximal increase of fluorescence during the chamber 
perifusion was practically the same for all compounds (240 s), the accumulation 
velocity by islets differed significantly (for gatifloxacin ~ 500 s, ciprofloxacin ~ 900 s, 
and moxifloxacin ~ 1100s). The time required for NAD(P)H to return to half its peak 
value (50% recovery time) was also analyzed as shown in Table 4.1.
Dividing the net fluorescence by the relative compound autofluorescence yields the 
normalized autofluorescence which is a measure of the amount of fluoroquinolone 
accumulated by the islet cells. The amount of ciprofloxacin in pancreatic islets is 3.7
fold higher and that of gatifloxacin is 2.1 fold higher than that of moxifloxacin.
4. Results                                 64
Table 4.1 Different accumulation of fluoroquinolones in pancreatic islets 
Net 
fluorescence 
signal at 0 
mM glucose
Net 
fluorescence 
signal at 20 
mM glucose
Glucose-
dependent 
increase
Relative 
compound 
fluorescence
Normalized 
fluorescence 
at 20 mM 
glucose
Relative 
islet
concen-
tration
Gatifloxacin 24.000 29.500 +22.9 % 5.4 5504 2.1
Ciprofloxacin 8.500 9.500 +11.8 % 1.0 9500 3.7
Moxifloxacin 46.500 64.500 +38.7 % 25.0 2580 1.0
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Figure 4.19 and Comparison between the 3 compounds in presence of 0 mM (A) and 20 mM 
glucose (B). It seems that the enhanced energetic caused by increasing glucose concentration affect the 
endogenous fluorescence of the fluoroquinolones. 
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Figure 4.20 The autofluorescence of Fluoroquinolones 100 µM in the presence of 20 mM glucose. 
The perifusion chamber contained no pancreatic islets.
4.2.3 Effects on NAD(P)H autofluorescence in pancreatic islets pre-incubated with 
fluoroquinolones
4.2.3.1 NMRI mice
Pre-incubation protocol was performed as the used fluoroquinolones had their own 
intrinsic fluorescence that interfered with the direct measurements of NAD(P)H signal 
intensity and to avoid the interference of the glucose metabolism with the cellular 
accumulation of the fluoroquinolones. In this type of experiments, the pancreatic islets
were pre-?????????? ???? ???? ????? ????? ???? ??? ??? ????? ??? ???? ?????? ?????? ???? ????? ????
islets were exposed to a challenge with 20 mM glucose followed by a 20 min perfusion 
at 0 mM glucose to test for reversibility. Similarly, washout experiments were 
performed by continuous perifusion with 0 mM glucose. 
When NMRI islets were pre-incubated with gatifloxacin, the autofluorescence was 
increased by 15 ± 10 % of the pre-stimulatory values and 30 % relative to the washout 
experiment. The autofluorescence values returned after glucose withdrawal. When 
perifusion was continued with 0 mM glucose, the values were progressively decreased 
to reach 72 % of the pre-stimulatory values (Fig 4.21).
When NMRI islets were pre-incubated with moxifloxacin, the autofluorescence of
NAD(P)H began to decrease so fast. Increasing glucose concentration to 20 mM 
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seemed to be ineffective to change NAD(P)H values throughout the whole 20 minutes 
of perifusion. The kinetic profile in the remainder 20 minutes of perifusion was 
parallel to the washout experiment (Fig 4.22).
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Figure 4.21 Changes in NAD(P)H signal in response to 20 mM glucose in NMRI mouse islets pre-
incubated with 100 ?M gatifloxacin at 36 °C. The islets were perifused with Krebs-Ringer medium 
containing 0 mM glucose for 20 minutes. The increase in NAD(P)H fluorescence was caused by glucose 
concentration 20 mM from second 1200 for 20 minutes. The effect is compared with wash out of 
gatifloxacin i.e. exposure of the islets to mKRB containing 0 mM during the whole 60 minutes protocol 
(the grey line) .Values are means ± SEM of 3 experiments for each. The values are normalized by setting 
the last pre-stimulatory value (20 min) to 100%.
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Figure 4.22 Changes in NAD(P)H signal in response to 20 mM glucose in NMRI mouse islets pre-
incubated with 100 ?M moxifloxacin at 36 °C. The islets were perifused with Krebs-Ringer medium 
containing 0 mM glucose for 20 minutes. The increase in NAD(P)H fluorescence was caused by glucose 
concentration 20 mM from second 1200 for 20 minutes. The effect is compared with wash out of 
moxifloxacin i.e. exposure of the islets to mKRB containing 0 mM during the whole 60 minutes protocol 
(the grey line) .Values are means ± SEM of 6 experiments for each. The values are normalized by setting 
the last pre-stimulatory value (20 min) to 100%.
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When NMRI islets were pre-incubated with ciprofloxacin, NAD(P)H autofluorescence 
decreased slowly until glucose concentration was increased to 20 mM where the values were 
increased by 45-60 % of the pre-stimulatory values and 60 % relative to the was out experiment. 
The values returned to pre-stimulatory level but not the level of the washout experiments (Fig 
4.23).
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Figure 4.23 Changes in NAD(P)H signal in response to 20 mM glucose in NMRI mouse islets pre-
incubated with 100 ?M ciprofloxacin at 36 °C. The islets were perifused with Krebs-Ringer medium 
containing 0 mM glucose for 20 minutes. The increase in NAD(P)H fluorescence was caused by glucose 
concentration 20 mM from second 1200 for 20 minutes. The effect is compared with wash out of 
ciprofloxacin i.e. exposure of the islets to mKRB containing 0 mM during the whole 60 minutes protocol 
(the grey line) .Values are means ± SEM of 3 experiments for each. The values are normalized by setting 
the last pre-stimulatory value (20 min) to 100%.
4.2.3.2 Islets of SUR1 KO mice
To test whether the inhibitory effect of the fluoroquinolones on the mitochondrial 
energetics was dependent on their effect on KATP channels, the NAD(P)H 
measurements were performed on islets from SUR1KO islets, which lack  functional 
KATP channels. The cultured SUR1 KO islets were pre-incubated for 1 h in the 
presence of 100 µM of each of the three drugs. As shown in Fig 4.24 A and B, the 
islets showed a response not less than that observed with normal NMRI islets. 
Increasing glucose concentration to 20 mM increased NAD(P)H autofluorescence by 
30 % of the pre-stimulatory values and 45 % relative to the washout experiment. 
Further kinetics revealed the return of values to the pre-stimulatory level. 
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Figure 4.24 Change in NAD(P)H fluorescence intensity in response to 20 mM glucose in SUR1 KO 
mouse islets at 36 °C. A) The islets were first perifused with Krebs-Ringer medium, containing the 0 mM 
glucose for 20 minutes (second 0 to 1200). This was followed by an increase in the glucose 
concentration to 20 mM (second from 1200 to 2400) and from 2400 seconds till the end again lowering 
the glucose concentration to 0 mM. The signal intensity (arbitrary units) is plotted against time in 
seconds. The grey line shows the effect of perifusion of the islets with only Krebs-Ringer solution without 
glucose. Values are means ± SEM of six experiments for each. The six pancreatic islets were obtained 
from 2 different preparations. B) The same protocol but the values are normalized by setting the last pre-
stimulatory value (20 min) to 100%. 
When the islets of SUR1 KO mice were pre-incubated with gatifloxacin, NAD(P)H 
autofluorescence decreased rapidly until glucose concentration was increased to 20 
mM, where the values increased by 4% of the prestimulatory values while 15 % 
relative to the washout experiment. The fluorescence values decreased to 90 % in the 
washout experiment (Fig 4.25 A and B).
When the islets of SUR1 KO mice were pre-incubated with moxifloxacin, the 
autofluorescence of NAD(P)H started to decrease so fast and again glucose 
concentration 20 mM failed to increase NAD(P)H values throughout the whole 20 
minutes of perifusion. The kinetic profile in the remainder time of perifusion was 
parallel to the washout experiment (Fig 4.26 A and B).
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Figure 4.25 Changes in NAD(P)H signal in response to 20 mM glucose in SUR1 KO mouse islets
pre-incubated with 100 ?M gatifloxacin at 36 °C. A) Glucose concentration increased to 20 mM (from 
1200 to 2400 seconds) and from 2400 seconds till the end again lowering the glucose concentration to 0 
mM. The signal intensity (arbitrary units) is plotted against time in seconds. The grey line shows the 
effect of perifusion of the islets with only Krebs-Ringer solution without glucose. Values are means ± 
SEM of six experiments for each. The islets were obtained from 2 different preparations. (B) The same 
protocol but the values are normalized by setting the last pre-stimulatory value (20 min) to 100%. 
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Figure 4.26 Changes in NAD(P)H signal in response to 20 mM glucose in SUR1 KO mouse islets
pre-incubated with 100 ?M moxifloxacin at 36 °C. A) Glucose concentration increased to 20 mM (from 
1200 to 2400 seconds) and from 2400 seconds till the end again lowering the glucose concentration to 0 
mM. The signal intensity (arbitrary units) is plotted against time in seconds. The grey line shows the 
effect of perifusion of the islets with only Krebs-Ringer solution without glucose. Values are means ± 
SEM of six experiments for each. The islets were obtained from 2 different preparations. (B) The same 
protocol but the values are normalized by setting the last pre-stimulatory value (20 min) to 100%. 
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When the islets were preincubated with ciprofloxacin, the fluorescence started to decrease till 
glucose concentration 20 mM was added causing immediate increase by 30-50% of the 
prestimulatory values and 60 % relative to the washout experiment. The values returned to pre-
stimulatory level when glucose was removed from the perifusion medium (Fig 4.27 A and B).
To sum up the results of pre-incubation protocol, the fluorescence increase was nearly 
unimpaired after ciprofloxacin, only modest after gatifloxacin and abolished after moxifloxacin. 
When compared to normal NMRI mice, it is clear that the inhibition of mitochondrial energetics 
by these fluoroquinolones is not secondary to a block of plasma membrane KATP channels but 
rather a purely primary effect.
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Figure 4.27 Changes in NAD(P)H signal in response to 20 mM glucose in SUR1KO mouse islets
pre-incubated with 100 ?M ciprofloxacin at 36 °C. A) Glucose concentration increased to 20 mM (from 
1200 to 2400 seconds) and from 2400 seconds till the end again lowering the glucose concentration to 0 
mM. The signal intensity (arbitrary units) is plotted against time in seconds. The grey line shows the 
effect of perifusion of the islets with only Krebs-Ringer solution without glucose. Values are means ± 
SEM of six experiments for each. The islets were obtained from 2 different preparations. B) The same 
protocol but the values are normalized by setting the last pre-stimulatory value (20 min) to 100%. 
4.2.4 FAD autofluorescence measurement in islets pre-incubated with fluoroquinolones
The same protocol for recording NAD(P)H autofluorescence was applied to measure 
FAD autofluorescence. Raising the glucose concentration to 20 mM resulted in a 
decrease by 25 % of the pre-stimulatory values and 35 % relative to the washout 
experiment. Although the values did not return to the prestimulatory values, they 
followed the level of washout experiments (Fig 4.28).
When NMRI islets were pre-incubated with gatifloxacin, increasing the glucose 
concentration resulted in a decrease of the intensity by 26 % which was closely similar 
to the control experiment. Compared to the washout experiment, the net decrease was 
38 %. When glucose was removed, the intensity showed a modest increase reaching to 
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75% of the prestimulatory values compared to 81 % for the washout experiment (Fig 
4.29).
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Figure 4.28 Changes in FAD signal in response to 20 mM glucose in NMRI mouse islets at 36 °C.
Islets pre-incubated for one hour with Krebs-Ringer medium (5 mM glucose). A decrease in fluorescence 
reflects an increase in the reduced state of flavins on exposure to 20 mM glucose which is reversible 
when glucose is no longer present in the medium. This was compared to perifusion the islets with only 
Krebs-Ringer medium with no glucose for the whole one hour (the grey line). Values are normalized by 
setting the last pre-stimulatory value (20 min) to 100%. 
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Figure 4.29 Changes in FAD signal in response to 20 mM glucose in NMRI mouse islets pre-
incubated with 100 ?M gatifloxacin at 36 °C. Glucose concentration increased to 20 mM (from 1200 to 
2400 seconds) and from 2400 seconds till the end again lowering the glucose concentration to 0 mM. 
The grey line shows the effect of perifusion of the islets with only Krebs-Ringer solution without glucose. 
Values are means ± SEM of six experiments for each. The islets were obtained from 2 different 
preparations. Values are normalized by setting the last pre-stimulatory value (20 min) to 100%. 
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When NMRI islets were pre-incubated with moxifloxacin, 20 mM glucose caused the 
intensity to slowly decrease by 20 % of the pre-stimulatory values and 5 % relative to 
the washout experiment. The intensities then followed similar kinetic profile for the 
rest of perifusion (Fig 4.30).
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Figure 4.30 Changes in FAD signal in response to 20 mM glucose in NMRI mouse islets pre-
incubated with 100 ?M moxifloxacin at 36 °C. Glucose concentration increased to 20 mM (from 1200 
to 2400 seconds) and from 2400 seconds till the end again lowering the glucose concentration to 0 mM. 
The grey line shows the effect of perifusion of the islets with only Krebs-Ringer solution without glucose. 
Values are means ± SEM of six experiments for each. The islets were obtained from 2 different 
preparations. Values are normalized by setting the last pre-stimulatory value (20 min) to 100%. 
When NMRI islets were pre-incubated with ciprofloxacin, the decrease caused by perifusion 
with 20 mM glucose was 20 % of the prestimulatory values and 30 % compared to washout 
experiment (Fig 4.31).
To sum up, the typical reaction to 20 mM glucose was sluggish but visible in each 
case. There were clear differences between the effect size after exposure to 
gatifloxacin, which was nearly unimpaired while after exposure to ciprofloxacin was 
clearly reduced and that after exposure to moxifloxacin, which was no longer 
significant
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Figure 4.31 Changes in FAD signal in response to 20 mM glucose in NMRI mouse islets pre-
incubated with 100 ?M ciprofloxacin at 36 °C. Glucose concentration increased to 20 mM (from 1200 
to 2400 seconds) and from 2400 seconds till the end again lowering the glucose concentration to 0 mM. 
The grey line shows the effect of perifusion of the islets with only Krebs-Ringer solution without glucose. 
Values are means ± SEM of six experiments for each. The islets were obtained from 2 different 
preparations. Values are normalized by setting the last pre-stimulatory value (20 min) to 100%. 
4.3 Measurement of ???
The inhibitory effect on the glucose-induced generation of reducing equivalents raised 
the question whether the fluoroquinolones affect the mitochondrial membrane 
potential. To address this possibility, the mitochondrial membrane potential was 
assessed using Rh123 (10 ?M). By monitoring Rh123 fluorescence levels over time, 
???????? ??? ???? ????? ???????????? ??? ????????? ??? ???????? ??? ?????????? ????? ???????????y 
and then after the addition of metabolic inhibitors.  The overall cellular fluorescence 
increases while the dye concentration inside mitochondria decreases and so loaded 
cells show a marked increase in fluorescence upon mitochondrial depolarization. 
When the ? cells of NMRI mice were perifused with 5 mM glucose, Rh123 
fluorescence was stable from minutes 20-60 of perifusion with no noticeable 
photobleaching. The intensity was then markedly increased by 15 ± 5 % in response to 
10 mM NaN3?? ?????? ??? ??????????? ????? ?? ?????????? ??? ???????????? ??? ????? ?????????? ???
more visible dye in the cytosol (Fig 4.32). Similar result?? ????? ????????? ????? ?? ?M
CCCP which is a powerful mitochondrial uncoupler that specifically increases the 
proton permeability of the inner mitochondrial membrane.  In contrast with the 
uncoupler CCCP, the effect of NaN3 was completely reversible. These findings 
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confirm those of previous studies (Krippeit-Drews et al., 2000; Kindmark et al., 2001) 
and support the validity of the technique to measure the metabolic activity of 
mitochondria. 
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Figure 4.32 Changes in mitochondrial membrane potential in the presence of a basal glucose 
concentration in NMRI ?? ?????. The cells were exposed to Krebs- Ringer medium containing 5 mM 
glucose for one hour showing a steady state from min. 20 onward. Addition of CCCP 5 ?M or Na N3 5 
mM for 20 minutes resulted in increased rhodamine-123 fluorescence, indicating depolarization of ??m
reaching up to 20 %. Results are means ± S.E.M. of results of 20 ? cells each from six experiments from 
two different preparations. Values were normalized to 100% at minute 20. 
4.3.1 Measurement of ??? with direct perifusion with fluoroquinolones
In the following set of experiments, NMRI ? cells were perifused with 5 mM glucose, 
then exposed to the fluoroquinolones for 30 minutes, followed by washout for 10 
minutes. Lastly either CCCP or NaN3 were applied to confirm the mitochondrial 
origin of the signal.
Addition of moxifloxacin to 5 mM glucose resulted immediately in a decrease of the 
fluorescence intensity by 5 % with a steady state reached after 4 minutes (Fig 4.33).
Furthermore, the responses of the ? cells to the metabolic inhibitors were not alike. While the 
fluorescence increase in response to azide was similar to the control (20% and 25 % 
respectively), the modest depolarization (10%) produced by CCCP did not continue for more 
than 3 minutes then returned rapidly to 100 % of pre-exposure to moxifloxacin (Fig 4.34).
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Figure 4.33 Effect of moxifloxacin on mitochondrial membrane potential in the presence of a 
basal glucose concentration in NMRI ?? ?????. Krebs-Ringer medium containing 5 mM glucose 
throughout the experiments, while ???????????????????????????????????????????????????????????????then
washed out from minute 50-??? ???????????????or 5 mM NaN3 added for 20 minutes. Moxifloxacin is 
associated with hyperpolarization immediately when added to the medium reaching steady state after 6 
minutes. The response of the ? cells to the uncoupler was increased by 20% but not last for more than 
two minutes then drops again, while response to azide was not affected. Values were normalized to 
100% at minute 20. 
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Figure 4.34 Comparison of the effect of CCCP and NaN3 on mitochondrial membrane potential
after wash out of moxifloxacin. The ? cells show unsustained decrease in Rh123 fluorescence with 
CCCP compared to steady state with NaN3. Values are means ± SEM of 27 and 16 ? cells respectively.
Values were normalized to 100% at minute 20. 
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In case of ciprofloxacin, the Rh123 intensity decreased only by 4 % and returned to the 
pre-stimulatory values with washout. Further depolarization by CCCP (increase by 15 
± 5 %) was similar to that of the control experiment (Fig 4.35).
In case of gatifloxacin, it caused only a decrease of Rh123 fluorescence by 6 % but not 
affected by washout for 10 minutes. Further perifusion with CCCP increased the 
fluorescence by 25 % (Fig 4.36).
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Figure 4.35 Effect of ciprofloxacin on mitochondrial membrane potential in the presence of a 
basal glucose concentration in NMRI ?? ?????. Krebs-Ringer medium containing 5 mM glucose was 
used throughout the experiments. Ciprofloxacin ???????????????????????????????????????????????????????
washed out from minute 50-????????????????????????from minute 60-80. The response of the ? cells 
appeared more or less the same as the control cells regarding exposure to ciprofloxacin and post wash 
out perifusion with the uncoupling agent. Values are means ± SEM of 27 ? cells. Values were normalized 
to 100% at minute 20. 
When the three drugs were compared concerning the effect on Rh123 fluorescence as 
well as the uncoupler CCCP, no significant differences was present between 
ciprofloxacin and control experiment. Moxifloxacin produced hyperpolarizing effect 
that persisted after washout and even dampened the uncoupler effect while it was 
without any influence on the azide induced-depolarization. The mild hyperpolarizing 
effect produced by gatifloxacin was not remarkable as with moxifloxacin (Fig 4.37).
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Figure 4.36 Effect of gatifloxacin on mitochondrial membrane potential in the presence of a basal 
glucose concentration in NMRI ?? ?????. Krebs-Ringer medium containing 5 mM glucose was used 
throughout the experiments. Gatifloxacin ???? ??? ????? ?????? ????? ??????? ??? ???? ????? ??? ????? ?????
washed out from minute 50-??? ????? ????? ?? ??? ?????? ???? ??? ???????? ???? ????????? ??? ???? ? cells 
appeared more or less the same as the control cells regarding exposure to gatifloxacin (except for small 
decrease in Rh123 fluorescence) and post wash out perifusion with the uncoupling agent. Values are 
means ± SEM of 32 ? cells. Values were normalized to 100% at minute 20. 
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Figure 4.37 Effect of the three fluoroquinolones on mitochondrial membrane potential in the 
presence of a basal glucose concentration in NMRI ???????. In the control experiments, the cells were 
perifused with mKRB 5 mM glucose for 1 hour, then CCCP was added from minute 60-80. Values were 
normalized to 100% at minute 20. 
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???????????????????m as a result of pre-incubation with fluoroquinolones
To determine the effect of fluoroquinolones on glucose-induced changes in 
mitochondrial membrane potential, ? cells were pre-incubated with 100 µM of each of 
the three compounds for 1 hour and then the effect of perifusion with 20 mM glucose 
on Rh123 fluorescence was examined. In control experiments, the hyperpolarization 
produced by the increase in glucose concentration to 20 mM was monitored followed 
by 0 mM glucose again for 20 minutes to test for reversibility. As shown in (Fig 4.38), 
raising the glucose concentration to 20 mM resulted in mitochondrial 
hyperpolarization as evidenced by the average decrease by 25 ± 5 % in Rh123 
fluorescence. When glucose was removed from the perfusion medium, fluorescence 
immediately started to return to 90% which attained also by washout experiment. 
In case of gatifloxacin, increase in glucose concentration resulted in a decrease in 
Rh123 fluorescence by 32-34 % after a lag of 3 minutes. The values returned to the 
pre-stimulatory level when glucose was removed from the medium. The washout 
experiment showed a slight decrease of fluorescence by 5 % after 25 minutes (Fig 
4.39).
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Figure 4.38 Effect of pre-incubation with mKRB 5 mM glucose on mitochondrial membrane 
potential in ? cells exposed to glucose 20 mM. The cells were perifused with Krebs-Ringer medium 
containing 0 mM glucose for 20 minutes. The signal intensity of Rh123 started to decrease in response to 
increased glucose concentration to 20 mM from for 20 minutes. The effect is compared with wash out i.e. 
exposure of the cells to KR containing 0 mM during the whole 60 minutes protocol (the grey line). Values 
are means ± SEM of 3 experiments for each (19 ? cells). Values were normalized to 100% at minute 20. 
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Figure 4.39 Effect of pre-incubation with gatifloxacin on mitochondrial membrane potential in ??
cells exposed to glucose 20 mM. The cells were perifused with Krebs-Ringer medium containing 0 mM 
glucose for 20 minutes. The signal intensity of Rh123 started to decrease in response to glucose 
concentration 20 mM for 20 minutes to reach steady state at minute 33. The effect is compared with 
wash out of gatifloxacin  i.e. exposure of the cells  to KR containing 0 mM during the whole 60 minutes 
protocol (the grey line). Values are means ± SEM of 3 experiments for each (25 ? cells). Values were 
normalized to 100% at minute 20.
In case of ciprofloxacin, fluorescence was stable till glucose 20 mM was applied 
causing slowly progressive decrease of the fluorescence by 20-25 % of the pre-
stimulatory values. This was followed by an incomplete return of the values to 88 % of 
the pre-stimulatory level when glucose was removed from the medium. The washout 
experiment showed slowly reduced fluorescence values by 8 % (Fig 4.40).
In case of moxifloxacin, increase in glucose concentration was followed by a decrease 
in Rh123 fluorescence by 32-35 % after a lag of 4 minutes. The values returned to 96 
% of the pre-stimulatory level when glucose was removed from the medium. The 
washout experiment showed reduced fluorescence values by 4 % after minute 40 (Fig 
4.41). 
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Figure 4.40 Effect of pre-incubation with ciprofloxacin on mitochondrial membrane potential in ??
cells exposed to glucose 20 mM. The cells were perifused with Krebs-Ringer medium containing 0 mM 
glucose for 20 minutes. The signal intensity of Rh123 started to reversibly decrease in response to 
increased glucose concentration to 20 mM for 20 minutes .The effect is compared with wash out of 
ciprofloxacin i.e. exposure of the cells  to KR containing 0 mM during the whole 60 minutes protocol (the 
grey line) .Values are means ± SEM of 3 experiments for each (22 ? cells). Values were normalized to 
100% at minute 20. 
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Figure 4.41 Effect of pre-incubation with moxifloxacin on mitochondrial membrane potential in ??
cells exposed to glucose 20 mM. The cells were perifused with Krebs-Ringer medium containing 0 mM 
glucose for 20 minutes. The signal intensity Rh123 started to reversibly decrease in response to 
increased glucose concentration to 20 mM for 20 minutes .The effect is compared with wash out of 
moxifloxacin  i.e. exposure of the cells  to KR containing 0 mM during the whole 60 minutes protocol (the 
grey line) .Values are means ± SEM of 3 experiments for each (31 ? cells). Values were normalized to 
100% at minute 20. 
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Comparison between pre-incubation of the three drugs on the Rh123 fluorescence was 
shown in (Fig 4.42). It seems that fluoroquinolones had a moderate hyperpolarizing 
effect of their own with varying degrees with the rank order: gatifloxacin and 
moxifloxacin > ciprofloxacin.
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Figure 4.42 Effect of pre-incubation with each fluoroquinolone on mitochondrial membrane 
potential in ?? cells exposed to glucose 20 mM. Comparison of the 3 compounds with the control 
experiments in which ? cells were only perifused with mKRB 0 mM glucose for one hour. Values were 
normalized to 100% at minute 20. 
???????????????????m on direct exposure to fluoroquinolones with stimulatory glucose
In this set of experiments, ? cells were exposed to 20 mM glucose for 20 minutes and 
then with such stimulatory glucose, fluoroquinolones were added. As seen in (Fig 
4.43), moxifloxacin was the only fluoroquinolone that reverse the depolarizing effect 
of 20 mM glucose reaching to 90 % of the pre-stimulatory value. This effect was 
similar to that when glucose 0 mM was used. On the contrary, both gatifloxacin and 
ciprofloxacin had not any influence on the glucose depolarizing effect.
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Figure 4.43 Effect of perifusion with each fluoroquinolone on mitochondrial membrane potential
in ??cells after being exposed to glucose 20 mM. The cells were perifused with mKRB 0 mM glucose 
for 10 minutes, increased to 20 mM from minute 10-???????????????????????????????????????????????????
from minute 30-50. In the control experiments, the cells were perifused with mKRB 0 mM from minute 30-
50. Values are means ± SEM of 3 experiments for each; gatifloxacin (25), moxifloxacin (32), ciprofloxacin 
(34), and control (18) ? cells. Values were normalized to 100% at minute 10. 
4.4 ATP/ADP ratio
Because the increase in the ATP-to-ADP ratio is fundamental for the initiation of ?
cell electrical activity and insulin secretion, the cytosolic adenine nucleotide levels and 
ADP/ATP ratio were examined. These measurements were performed on statically 
incubated islets, where the conditions were chosen to fit to pre-incubation scheme i.e.
the islets were incubated for 1 h in the presence of 100 µM of the fluoroquinolones, 
then the medium was replaced and after 20 min the glucose concentration was raised 
from 0 to 20 min as shown in (Fig 4.44). At the end of the 20 min exposure to high 
glucose, the adenine nucleotide content was measured. Only moxifloxacin, but neither
gatifloxacin nor ciprofloxacin significantly affected the ATP/ADP ratio. The reduction 
of the ratio was of moderate extent (down to 81.4 + 3.3 %), but was highly significant 
(p = 0.0078, Wilcoxon signed rank test). For comparison, the uncoupler CCCP (5 µM) 
reduced the ATP/ADP ratio to 43 %. In the presence of 5 mM glucose, the acute 
addition of the fluoroquinolones was without effect on the ATP/ADP ratio (Fig 4.45).
Since the inability of 100 ?M of the fluoroquinolones to depolarize the beta cells in the 
perforated patch configuration (in spite of the depolarizing effect on open cell 
preparations) had been found when the glucose concentration in the cell bath was 5 
mM, the immediate effect of fluoroquinolones on the adenine nucleotide content was 
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determined. To make the experimental situation comparable to the 
electrophysiological measurements, the exposure time was limited to 30 min. 
However, it turned out that none of three compounds significantly reduced adenine 
nucleotide content or the ATP/ADP ratio. 
To assess the dependency of the above-described effect of moxifloxacin on the glucose 
concentration in the medium or, more generally, the energization of the beta cells, the 
effect of 100 µM moxifloxacin on the adenine nucleotide content was determined in 
the presence of 0 mM glucose and in the presence of 5 mM glucose plus 5 µM of the 
uncoupler of oxidative phosphorylation, CCCP. Here, the exposure time was 20 min to 
be comparable to experiments in which the mitochondrial membrane potential was 
determined (see Figure 4.33). The absence of glucose was clearly recognizable by the 
diminished ATP content (compare Figure 4.45), which was further reduced by CCCP.  
However, there was no significant change by the presence of moxifloxacin. The 50% 
reduction of the ATP-to-ADP ratio in the combined presence of moxifloxacin and 
CCCP corresponded to the effect of CCCP alone in earlier experiments of the group.
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Figure 4.44 Effect of 100 µM of gatifloxacin, ciprofloxacin or moxifloxacin on the adenine 
nucleotide content and the ATP-to-ADP ratio as established by a 20 min exposure to 20 mM 
glucose. Freshly isolated islets were statically incubated for 1 h in KR medium containing 5 mM glucose 
and the respective fluoroquinolone. Then, the KR medium was replaced by one containing 0 mM glucose 
and after 20 min the glucose concentration was raised to 20 mM and the incubation was continued for 
another 20 min. Thereafter the incubation was stopped and the adenine nucleotide content was 
determined. The ratio value of each single control experiment was normalized to 100%. The data are 
means ± SEM of 7 experiments.
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Figure 4.45 Effect of 100 µM of gatifloxacin, ciprofloxacin or moxifloxacin on the adenine 
nucleotide content and the ATP-to-ADP ratio in the presence of 5 mM glucose. Freshly isolated 
islets were statically incubated for 20 min in KR medium containing 5 mM glucose, then the respective 
fluoroquinolone was added and the incubation was continued for another 30 min. Thereafter the 
incubation was stopped and the adenine nucleotide content was determined. The ratio value of each 
single control experiment was normalized to 100%. The data are means ± SEM of 8 experiments.
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Figure 4.46 Effect of 100 µM of moxifloxacin on the adenine nucleotide content and the ATP-to-
ADP ratio in the presence of 0 mM glucose or 5 mM glucose plus uncoupler. Freshly isolated islets 
were statically incubated for 20 min in KR medium containing either 0  mM glucose or 5 mM glucose plus 
5 µM CCCP. Moxifloxacin was present from the beginning of the incubation. After 20 min the incubation 
was stopped and the adenine nucleotide content was determined. The ratio value of each single control 
experiment was normalized to 100%. The data are means ± SEM of 7 experiments.
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4.5 Ultrastructural changes induced by preincubation with fluoroquinolones
To assess whether the functional changes in the beta cell energy metabolism, which had become 
visible in the microfluorometric measurements, can lead to morphological alterations, freshly 
isolated islets were cultured for 24 h in RPMI medium containing 5 mM glucose and one of the 
fluoroquinolones selected for this study. For control purpose, islets were also cultured in the 
absence of a fluoroquinolone. Each compound was tested at two concentrations, 10 and 100 µM. 
100 µM was selected because this was the concentration mainly employed for the functional 
tests. 10 µM was chosen because it is within the range of peak plasma concentrations and 
because the long term exposure might reveal changes not visible during 120 min or 1h 
perifusions. The electromicrographs were evaluated with respect to the following criteria: 
granulation state of the beta cells, configuration of the rough endoplasmic reticulum (RER) 
configuration of the Golgi apparatus and mitochondrial morphology.
The control-cultured islets showed a well preserved morphology, in particular practically all of 
the beta cells within these islets showed a marked granulation. After exposure to 10 µM 
gatifloxacin a moderate degranulation was observed (~ 50 % of the beta cells) and the RER was 
elongated, but no changes were visible in the Golgi apparatus or the mitochondria (Fig 4.47A). 
100 µM of gatifloxacin produced a more marked but still not a complete degranulation (~ 30% 
of the beta cells well granulated). The RER was now also dilated and the mitochondria showed a 
number of fusion- and- fission configurations (Fig 4.47B). However, there were no signs of 
outright mitochondrial damage of cell death.    
After exposure to 10 µM ciprofloxacin at best a modest degranulation was observed (~ 70 % of 
the beta cells well granulated) and the RER, the Golgi apparatus and the mitochondria showed a 
control-like morphology (Fig 4.48A). 100 µM of ciprofloxacin however produced a strong 
degranulation, potentially stronger than the one by gatifloxacin (only about 10 – 15 % of the 
beta cells being well granulated). In contrast to gatifloxacin at the same concentration 100 µM 
ciprofloxacin did not affect the configuration of the RER and the Golgi apparatus. However, 
similar to gatifloxacin, the mitochondria showed clear changes, their size being enlarged and 
fusion- and –fission configurations being visible (Fig 4.48B). 
After exposure to 10 µM moxifloxacin ~ 50% of beta cell was degranulated, similar to what has 
been observed with gatifloxacin. Also, there were no clear-cut changes in the appearance of the 
RER, the Golgi apparatus and the mitochondria (Fig 4.49A). After exposure to 100 µM of 
moxifloxacin, a degranulation was unmistakable (only about 30 % of the beta cells being well 
granulated). 100 µM moxifloxacin did not affect the configuration of the RER and the Golgi 
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apparatus. However, similar to the other fluoroquinolones the mitochondria were occasionally 
enlarged and fusion- and –fission configurations appeared (Fig 4.49B). 
A
B
Figure 4.47 Ultrastructural changes produced by culturing NMRI islets in and RPMI 
containing 5mM glucose and gatifloxacin (10 or 100 µM) for 20h. A) Effect of 10 µM: Note
the enlarged RER (arrow) and the ? cell showing partial degranulation (asterisk) compared to 
the neighbouring ? cells. B) Effect of 100 µM: Note the elongated mitochondrion (upper circle) 
and the mitochondria showing fusions (lower circle) in addition to the increased intercellular 
space (arrow head) that may correlate with degranulation observed. Magnification 8000 x
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Figure 4.48 Ultrastructural changes produced by culturing NMRI islets in and RPMI 
containing 5mM glucose and ciprofloxacin (10 or 100 µM) for 20h. A) Effect of 10 µM: 
Note the elongated mitochondria (M1 and M2) and the mitochondrion showing fusion (M3).The 
arrow heads point to the increased intercellular space. B) Effect of 100 µM: Note the elongated 
mitochondrion (lower circle) and multiple mitochondria showing fusions (upper circle) in 
addition to the increased intercellular space (arrow head) that may correlate with degranulation 
observed. Degranulation is more widespread than with100 µM gatifloxacin. Magnification 8000
x
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Figure 4.49 Ultrastructural changes produced by culturing NMRI islets in and RPMI
containing 5mM glucose and moxifloxacin (10 or 100 µM) for 20h.A) Effect of 10 µM: The 
arrow heads point to the increased intercellular space and occasional elongated mitochondria 
(M). B) Effect of 100 µM: occasionally elongated mitochondrion and multiple mitochondria (M) 
showing fusions in addition to the increased intercellular space (arrow head) that may 
correlate with degranulation (asterisk) observed. Degranulation is more widespread than 
with100 µM moxifloxacin. Magnification 8000 x
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5. Discussion
This study was carried out to explore the cytotoxic effects of fluoroquinolones and possible 
mechanism(s) that could explain their dysglycemic complication. 
5.1 Digestion and culture of the pancreatic islets as well as ??cells
The isolation of pancreatic islets using collagenase solution had begun with the pioneer work of 
Moskalewski (1965). Later on, Lacy and Kostianovsky (1967) introduced an islet isolation 
technique in rats that involved the ductal distension of the pancreas and collagenase digestion.
Differences among various batches of collagenase including enzyme activity, purity, and 
formulation strongly influence the outcome of the islet isolation. Collagenase had been tested by 
Wolters et al. (1992) and de Haan et al. (2004) for proper digestion of rat islets. Bucher et al.
(2004) also concluded that Serva collagenase was as effective as Liberase (Roche) in terms of 
islet yields and function. It might be argued that mouse islets are more vulnerable than rat islets
to any potential deleterious effect of the collagenase during the isolation procedure. On the 
contrary, the integrity had been proved to be preserved by others (Zawalich et al., 2004). 
Animal’s age can influence the numbers of islets obtained. Although younger mice (less than 12 
weeks) can give high yields of the islets, the injection into the small cholecystic duct was not 
practically feasible. Nevertheless, there are many factors that contribute to immaturity of ? cells 
and diminished insulin secretory response to glucose and other secretagogues in neonatal cells
compared with adult cells (Navarro-Tableros et al., 2007). 
Studies of optimal culture conditions demonstrated that RPMI 1640 with serum maintains or 
augments glucose-stimulated insulin secretion in murine islets (Andersson, 1978). The role of 
serum for GSIS, insulin biosynthesis and islet cell survival had been confirmed (Ling and 
Pipeleers, 1994). Glucose concentration in the culture medium is at the centre of a delicate 
balance between necessary source of energy and islet toxicity. The choice of the glucose 
concentration of 5 mM was made so as not to stimulate the glucose metabolism during the 
cultivation period (Gilon et al., 1994) as extended exposure to high glucose may cause toxicity 
(Robertson et al., 2003). A???????????????-cell apoptosis has also been reported in rodent islets 
and insulin-secreting MIN6 cells cultured up to one week in the presence of a low non-
stimulating glucose concentration (Efanova et al., 1998; Van de Casteele et al., 2003). However, 
in the current study, no negative effects were observed. This was exemplified by the response of 
the islets ?????????????? to potassium depolarization (calcium measurements) and response to 20 
mM glucose when different parameters of mitochondrial energetics had been recorded. On the 
other hand, when the islets were incubated with 10 mM glucose, the functional integrity was 
compromised.
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For each test series, pancreatic islets from two different preparations were used to eliminate the 
possibility of islet-to-islet communication that might be claimed to be responsible for the 
particular biological behaviour of islets (Giordano et al., 1993; Nunemaker et al., 2005). 
The pancreatic islets with a small diameter were preferentially chosen as their functional 
integrity was often less compromised during their cultivation phase (Gilon et al., 1994) and the 
loading with the indicator was more homogeneous (Gilon et al., 1994; Nadal et al., 1999). 
Notably, large islets were more prone to central necrosis than small islets (Cui et al., 2005;
Lehmann et al., 2007).
This "injection method" when compared to "conventional" digestion method had 3 advantages:
1. Free islets recovered from the pancreas were significantly more (150-200 islets / per 
pancreatic mouse) as perifusion through the pancreatic duct allowed collagenase to 
access the islets using anatomical structures.
2. The pancreatic islets during this isolation procedure were subjected to less mechanical 
damage (Carter et al., 2009).
3. The time required for attachment of the pancreatic islets to the cover slips was clearly 
diminished (12 -24 h) in comparison to that obtained using the "conventional" method 
(48-72 h). 
Although Ca2+ signals can be registered with a higher temporal resolution ??????????????????? the 
pancreatic islets represent a good model to evaluate the effect of fluoroquinolones on [Ca2+]i for 
the following reasons:
1. It allowed a direct comparison with results from experimental studies to determine the 
rate of insulin secretion. When dispersed, ? cells exhibit multiple metabolic glucose-
response populations with different insulin secretion properties (Bennett et al., 1996). In 
the intact pancreatic islets, intercellular signalling can occur via both chemical 
(paracrine; Rorsman et al., 1989; Salehi et al., 2005) and electrical signals (via gap 
junctions; Meda, 1996; Charollais et al., 2000). Both pathways of communication are 
disrupted when the islet is dissociated into single cells.
2. Studies of the intact islet reflect interactions between different cell types. The effects of 
non-dispersed ? cells in an intact pancreatic islet are the more actual physiological 
conditions than individual ? cells (Pipeleers et al., 1982; Jain and Lammert, 2009).
All experimental protocols were performed at a temperature of 35-36°C as cooling had been 
shown to inhibit not only the glucose-induced [Ca2+]i rise but also Ca
2+-activated exocytosis 
(Niwa et al., 1996; Kinard and Satin , 1996).
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5.2 Effects of fluoroquinolones on stimulus secretion coupling 
5.2.1 Depolarizing effect 
When exploring the mechanism of fluoroquinolone-induced insulin release, we first considered 
the KATP channel-dependent mechanism for glucose-stimulated insulin secretion (Maeda et al., 
1996). It is generally accepted that a high degree of blockade of the KATP channel with a 
subsequent depolarization of the plasma membrane of ? cells (in mice) stimulates insulin 
secretion even at very low glucose concentrations (Ashcroft and Ashcroft, 1990; Panten et al., 
1992). It is generally believed that compounds with a direct blocking effect on KATP channels act 
as both initiators and enhancers of insulin secretion (Rustenbeck et al., 1997b; Bleck et al., 
2004). However, it seems that the greater glucose dependence of fluoroquinolones effects on 
insulin secretion was not simply a function of KATP channel closure. The results obtained in the 
perforated patch mode (i.e. using metabolically intact ? cells exposed to 5 mM glucose) resolved 
several of these contradictions (Ghaly et al., 2009). Using 100 ?M of ciprofloxacin, gatifloxacin 
and moxifloxacin were virtually ineffective, corresponding to the lack of insulinotropic effect at 
5 mM glucose. The loss of potency in the perforated patch mode (fig 5.1), as compared to the 
whole cell mode (fig 5.2), may be explained by the hypothesis that the inhibition of KATP
channel activity by fluoroquinolones was susceptible to negative modulation by endogenous 
compounds, which were present in metabolically intact ? cells, but not in open ? cells (whole 
cell mode), where the cytosol was washed out by the pipette solution (Rustenbeck et al., 1997a; 
Strauss et al., 2001). In this context, the observation by Saraya et al. (2004) that gatifloxacin was 
more potent to block reconstituted Kir 6.2/ SUR1 channels in HEK cells (Human Embryonic 
Kidney) than to block native KATP channels in MIN6 cells can be seen as indirect evidence for 
the existence of negative modulators in insulin-secreting cells.
5.2.2 Effects of fluoroquinolones on [Ca2+]i
5.2.2.1 Effects on [Ca2+]i in NMRI mice
Numerous experiments conducted over many years have established that insulin secretion is 
calcium dependent (Satin, 2000) as a result of blockade of KATP channels (Valdeolmillos et al., 
1992). As depolarization leads to the opening of VDCC channels producing an increase in 
[Ca2+]i, which stimulates insulin granule exocytosis (Renström et al., 1996), so the next step was 
to measure [Ca2+]i . Fura-2 is currently very popular Ca
2+ indicator. The larger fluorophore of 
Fura-2 (compared to quin-2) gives it slightly longer wavelengths of excitation compatible with 
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glass microscope optics, a larger extinction coefficient and a higher quantum efficiency (Tsien, 
1989). 
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Figure 5.1 Comparison of the depolarizing effect of fluoroquinolones on metabolically intact ?????????????-cells. Original registrations of the effect of 100 ?M of gatifloxacin (A), ciprofloxacin (B) and 
500 ?M gatifloxacin (C) on the membrane potential of mouse pancreatic ? cells in the perforated patch 
configuration. At 100 ?M none of the fluoroquinolones elicited a depolarization. Note the effect of 100 ?M 
of efaroxan in the presence of 100 ?M gatifloxacin or ciprofloxacin (A and B). Increasing gatifloxacin 
concentration from 100 to 500 ?M led to action potential spiking interrupted by short phases of 
repolarisation (C). Typical registrations were made of 3–4 experiments.
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Figure 5.2 Depolarization of the membrane potential of mouse pancreatic ??cells by ciprofloxacin 
(A), moxifloxacin (B). Original registrations of the membrane potential of cultured mouse ? cells were 
done using the conventional whole cell-configuration. Initially, the fluoroquinolone concentration was 
50 ?M, which was increased to 100 ?M when a steady state was apparently reached. Typical 
registrations were made of 4–7 experiments.
5. Discussion                           93
The microfluorometric measurements of fluoroquinolone induced [Ca2+]i ???????????? cells was 
difficult to be assessed because the endogenous fluorescence of the fluoroquinolones (Idowu and 
Peggins, 2004) interfered with the Fura-fluorescence. The use of D600 confirmed that the [Ca2+]i
increase was due to depolarization-induced influx of Ca2+ via L-type Ca2+channels (Dryselius et 
al., 1999).
At non-stimulatory glucose concentration, neither of the 3 drugs had proved to affect [Ca2+]i
except when the concentration was increased from 100 to 500 ?M, which was far above the 
maximal serum level in healthy subjects during therapeutic dosages. Only 500 ?????????????????
produced an increase [Ca2+]i that was irreversible even by the use of D600 or calcium free 
perifusion medium, where tolbutamide effect disappeared, indicating that release from internal 
stores may play an additional role (Loo et al., 1997). 
In the presence of 10 mM glucose, both gatifloxacin and moxifloxacin induced a strong increase 
of [Ca2+]i whereas ciprofloxacin was moderately effective. The marked [Ca
2+]i increase by 
gatifloxacin fits to the secretory characteristics. This had been successfully, though 
incompletely, counteracted by K+ channel opening using diazoxide while the remaining effect 
was further reduced by the calcium channel blocker D600. The moderate but continuing [Ca2+]i
increase by ciprofloxacin and the magnitude of the moxifloxacin-induced increase of [Ca2+]i
were unexpected. These observations concur with the marked enhancing effect of ciprofloxacin 
and moxifloxacin on secretion when the glucose concentration was raised to a stimulatory level. 
Unlike sulfonylureas, it seems that fluoroquinolones are not stimulatory for insulin secretion but 
rather enhance the glucose induced secretion (Ashcroft, 2000). Rather, this mode of action 
resembles that of imidazolines (Rustenbeck et al., 1997b; Proks and Ashcroft, 1997). They
enhance the effect of a stimulatory concentration of glucose-induced insulin secretion by
activation of KATP channel via the pore-forming Kir6.2 subunit (Rustenbeck, 1999; Grosse-
Lackmann et al., 2003). The presence of SUR1 either increased the affinity of the binding site, 
or enhanced the efficacy with which drug binding is converted into channel closure (Zünkler
et al., 2006).
To confirm the functional integrity of the cultured pancreatic islets/ ? cells, they were
exposed to a maximum of depolarizing K+ concentration. This stimulus, regardless of 
the glucose concentration, evoked an increase in the effective cytosolic Ca2+
concentration (Gilon and Henquin, 1992; Rustenbeck, 1999).
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5.2.2.2 Effects on [Ca2+] i in SUR1 knockout mice
The SUR1 knockout mouse model was used to study possible effects of fluoroquinolones on 
depolarization independent-Ca2+ transport. SUR1 knockout mice were used instead of the
pharmacological inhibitors with which non-specific effects can never be entirely excluded.
Although this kind of KATP-channel-deficient mice were used to test the amplifying pathway, but
signals of a triggering pathway were supposed to exist (Haspel et al., 2005). This transgenic 
animal model was developed in a working group by Lydia Aguilar-Bryan and Joseph Bryan 
(Seghers et al., 2000). As both Kir6.2 and SUR1 subunits are normally required for functional 
expression of the KATP channel, the inactivation of SUR1 part based on the mutation of the 
ABCC8 coding gene prevented the constitution functional channel (Inagaki et al., 1995b; 
Zerangue et al., 1999). The SUR1 gene is located within a region on chromosome 11 and was 
reported to be linked to hyperinsulinemia of infancy (Thomas et al., 1995).
The physiological and functional properties of both SUR1KO pa????????????????????????????????
cells were characterized in some working groups (Seghers et al., 2000; Nenquin et al., 2004; 
Marhfour et al., 2009). The absence of functional KATP channels was associated with a partial 
depolarization of the plasma membrane, with continuous Ca2+ action potentials and increased 
[Ca2+]i values independently from extracellular glucose concentration (Düfer et al., 2004;
Szollosi et al., 2007). The ability of isolated SUR1KO islets to respond to a maximum K+
concentration, irrespective of the KATP channel, was used as an internal standard (Szollosi et al., 
2007)
Gatifloxacin was the most efficient to increase [Ca2+]i followed by ciprofloxacin and then lastly 
moxifloxacin. The partial antagonism brought about by D600 with gatifloxacin and 
ciprofloxacin and modest one seen with moxifloxacin, still implicating Ca2+ influx via L-type
Ca2+ channels. However, knockout ? cells have a chronically elevated [Ca2+]i because the 
smaller K+ conductance leads to a partial depolarization. It appears that this increase of [Ca2+]i is 
not related to stimulated insulin secretion since fluoroquinolones did not enhance insulin 
secretion from SUR1KO islets (Ghaly et al., 2009), also moxifloxacin did not produce 
dysglycemia in diabetic patients (Barth and Landen, 2003; Lipsky et al., 2007; Vick-Fragoso et 
al., 2009). Dissociations between [Ca2+]i increases and stimulation of secretion have been found 
earlier (Zaitsev et al., 1995).
The moderate [Ca2+]i increase by fluoroquinolones in islet cells from SUR1KO mice, which do 
not have functional KATP channels, suggests that fluoroquinolones may have additional sites of 
action by which [Ca2+]i is affected. Cytosolic calcium rises are relayed to mitochondria, where 
the signal is amplified (Kennedy et al., 1996). While calcium influx across the plasma 
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membrane is the primary signal for insulin granule exocytosis, the recruitment of granules 
depends on cellular energy metabolism (Varadi et al., 2002). Calcium has been proposed to 
modulate mitochondrial function with a direct impact on intermediary metabolism, substrate 
oxidation and energy production.
5.2.3 Effect on reducing equivalents
As fluoroquinolones (100 µM) depolarized open cell preparations of ??cells, but none of these 
compounds de???????????????????????? ???????? cells which was only seen using 500 µM, so an 
interference with energy metabolism was supposed to play a role. Certain parameters of the 
mitochondrial energetics had been examined; namely NAD(P)H, FAD, ??m  , ΑTP/ADP ratio.
Therefore, fluorescence measures of NAD(P)H and FAD can be used as a measure of 
intracellular redox state (Chance et al., 1979). Flavoproteins signals have been used much less 
than NAD(P)H signals in st?????? ??? ?? ???l energetics. However flavoprotein autofluorescence 
had also been demonstrated to have significant utility for studies of mitochondrial energetics in ?
cells and HIT cell line (Panten and Ishida, 1975; Duchen, et al., 1993; Civelek et al., 1996). The 
signals generated were assumed to be due to mitochondrial dynamics. Early work concluded that 
multiple flavoproteins were involved in mitochondrial electron transfer and were thereby 
coupled to NADH utilization by the electron transport chain (Scholz et al., 1969). Many studies 
demonstrated that flavoprotein metabolic signals could be more direct measures of oxidative 
metabolism and less contaminated by cytosolic processes than NAD(P)H measurements 
(Shuttleworth, 2010).
The used protocol to elicit recognizable changes was to increase glucose concentration to 20 
mM which increased both ? cell FAD and NAD(P)H fluorescence with minimal contribution 
from non ? cell (Quesada et al., 2006; Smelt et al., 2008). 
In contrast to the heterogeneous responses produced in isolated ? cells, glucose induced a 
uniform increase in NAD(P)H autofluorescence in ? cells residing within intact islets (Bennett et 
al., 1996). Experiments where exposure to the fluoroquinolones took place in the presence of 
glucose showed contribution of fluoroquinolones much higher than that of NAD(P)H. Increased 
cellular accumulation may be due to increased uptake into the mitochondria. However, indirect 
effect by ATP-dependent processes is also possible. Cellular accumulation of fluoroquinolones 
was also reported with gatifloxacin using the primary cultured rat brain micro-vessel endothelial 
cells (rBMECs) as an in vitro model for transport across blood brain barrier (Li et al., 2009). For 
moxifloxacin, the use of sodium fluoride, azide, and cyanide interfered with the transport of the 
drug into the phagosomes (Hall et al., 2003) and similar observations were made in human 
polymorphonuclear leucocytes (Pascual et al., 1999). Ciprofloxacin accumulation in 
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polymorphonuclear leucocytes had been attributed to protein kinase C up-regulation (Walters 
and Nakkula, 2003).
When the islets were pre-incubated with the drugs for one hour, the increase of NAD(P)H 
autofluorescence, that was typically elicited by 20 mM glucose, was abolished by moxifloxacin
treatment but only moderately reduced by ciprofloxacin or gatifloxacin. The same effect was 
observed using islets of SUR1KO mice indicating that this inhibitory effect was independent on 
the blocking effect that fluoroquinolones exerted on the KATP channels considering that the 
glucose metabolism in SUR1KO islets was not altered. The NAD(P)H results of control 
experiments of SUR1KO islets reflected the unimpaired oxidation of glucose which is in 
accordance with Szollosi et al. (2007).
Although the three fluoroquinolones increased [Ca2+]i with variable magnitude, but the net effect 
of [Ca2+]i on NAD(P)H autofluorescence is dependent upon the degree of respiratory chain flux, 
and may represent a balance of activation of calcium sensitive mitochondrial dehydrogenases on 
one hand, and Ca2+-induced NAD(P)H oxidation on the other (Civelek et al., 1996).
Concerning FAD, moxifloxacin and, to a lesser degree, ciprofloxacin attenuated the glucose-
induced decrease of autofluorescence which was a more specific indicator of the intra-
mitochondrial production of reducing equivalents (Husson et al., 2007). On the other hand, 
gatifloxacin produced an effect close to the control experiment.
5.2.4 Mitochondrial membrane potential
Central to mitochondrial function is an electrochemical proton gradient across the mitochondrial 
inner membrane that is established by the proton pumping activity of the respiratory chain. The 
proton gradient establishes a proton-motive force, which has two components: a pH differential 
and an electrical membrane potential (??m). The pH component of mitochondrial proton motive 
force is small relative to the membrane potential and, hence, it is the latter that provides the 
predominant driving force (Campanella et al., 2009).
It seems that moxifloxacin, and to lesser extent gatifloxacin, causes hyperpolarizing effect in the 
presence of non-stimulatory glucose level. Interestingly, only moxifloxacin somewhat reduced
the effect of uncoupler CCCP even when wash out while the effect of azide is still preserved 
suggesting that moxifloxacin may have some effect on the respiratory chain. Ciprofloxacin had 
neither effect on the mitochondrial membrane potential nor on the uncoupler.
Ideally, the effect of fluoroquinolones on mitochondrial membrane potential was to be 
demonstrated with the same experimental conditions under which the effect on the reducing 
equivalents was measured. However, when the pre-incubation protocol was used (which was not 
necessary since the fluorescence excitation of Rh123 and that of fluoroquinolones did not 
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overlap) there was no effect of the fluoroquinolones. This surprising lack of effect may be 
explained by the hyperpolarizing effect of the fluoroquinolones in the presence of 5 mM glucose 
(above). Thus, it can be assumed that a possible reduction of the glucose induced 
hyperpolarization was offset by the direct hyperpolarizing effect of the fluoroquinolones
themselves. This assumption proved to be correct when the fluoroquinolones were added after 20 
mM glucose had led to hyperpolarization. Again moxifloxacin was the most efficient compound 
to diminish the glucose induced hyperpolarization. 
This may be explained by that the islet mitochondria appeared to be more energized in 
comparison to the mitochondria from dispersed ? cells. The differences in mitochondrial energy 
storage may be due, in part, to the higher levels of [Ca2+]i in dispersed ? cells, which, in turn, 
may depolarize (??m)  to a greater extent. The elevated calcium levels observed in dispersed ?
cells could have an effect on communication between the mitochondria and the cell membrane. 
The incorporation ??? ? cells into islet thus may help them to maintain a larger mitochondrial 
gradient for increased ATP production (Nunemaker and Satin, 2004).
5.2.5 Effect on ATP/ADP ratio
Since the data so far suggested that the inhibitory effect of fluoroquinolones on the 
mitochondrial energy metabolism, it was of interest to measure the islet content of ATP and 
ADP as well as ATP/ADP ratio.
When the pre-incubation protocol was performed, neither gatifloxacin nor ciprofloxacin 
significantly affected the ATP/ADP ratio. Only moxifloxacin significantly reduced ATP/ADP 
ratio which is confirmatory to its inhibitory effect on mitochondrial energetics. This effect was 
not observed using basal glucose concentration which corresponds to the absence of 
depolarizing effect of moxifloxacin in the perforated patch mode. 
While a correspondence could be found between the marked effect of moxifloxacin on the 
NAD(P)H fluorescence and the effect on adenine nucleotide content of pancreatic islets, no such 
relation was apparent when the direct effect of fluoroquinolones was tested in the presence of 5 
mM glucose. This experimental protocol had been chosen because measurements of the 
mitochondrial membrane potential using the indicator Rh123 had shown that the 
fluoroquinolones exert a hyperpolarizing effect. Theoretically, this could be due to an increased 
offer of reducing equivalents to the respiratory chain (this causes the hyperpolarization by 20 
mM glucose) (Duchen et al., 1993), however, the more likely explanation would be that the 
respiratory chain was inhibited by the fluoroquinolones at a distal site with an unchanged offer 
of reducing equivalents from the Krebs cycle (Rustenbeck et al., 1997a). Apparently, this 
inhibition if it takes place cannot reach the threshold to reduce the oxidative phosphorylation
5. Discussion                           98
(Gallagher et al., 1986; Rossignol et al., 2003). An alternative explanation could be that the 
fluoroquinolones somewhat reduce the proton leak across the inner mitochondrial membrane. 
This would fit to the observation that moxifloxacin apparently counteracted the depolarization 
by CCCP. On the other hand, this reduced depolarization did not translate into a diminished 
effect of CCCP on the adenine nucleotide content. 
While the adenine nucleotide measurements by themselves contain logic in that the offer of 
glucose or the uncoupling of the respiratory chain lead to the expected effects, the effect of the 
fluoroquinolones is less straightforward to interpret than expected. There is scarce literature 
dealing with the effects of fluoroquinolones on ? cell mitochondria. Meanwhile the inhibitory 
effect of some fluoroquinolones on mitochondrial functions was observed in primary human 
osteoblasts and tendon cells (Duewelhenke et al., 2007; Lowes et al., 2009). To further clarify 
the mechanism of action at the mitochondria will require the measurement of an additional 
parameter, namely the oxygen consumption. Only by this way, it will be possible to determine 
whether the changes in membrane potential are due to inhibition of the respiratory chain 
enzymes or to changes in the proton leak size.
It is not surprising that quinolones can compromise the mitochondrial energetics as antibacterial 
agents are commonly known to impair mitochondrial function, some acting as inhibitors of 
mitochondrial RNA and protein synthesis (Zhang et al., 2005), while others acting as inhibitors 
or uncouplers of oxidative phosphorylation (Gallagher et al., 1986).
5.2.6 Ultrastructural changes induced by fluoroquinolones
In the functional experiments the exposure to the fluoroquinolones was much shorter than during 
an antibiotic therapy, i.e. 1 h vs 72 h (most of the fluoroquinolone-induced hypoglycaemias 
occur during the first 3 days). As so often in pharmacology the compressed time scale was 
compensated by increased concentration. 100 µM was the concentration which regularly 
produced an increase in insulin secretion when the glucose concentration was stimulatory (10 
mM). This is why this concentration was chosen for the experiments to characterize the 
mitochondrial effects. On the other hand, it is clearly above the peak plasma concentrations even 
though not completely beyond measure. For this reason the effect of 10 µM and 100 µM of the 
three selected fluoroquinolones on beta cell ultrastructure was investigated. The 
electromicrographs confirmed that fluoroquinolones enhance the insulin secretion, since at 100 
µM a degranulation was clearly visible. The nearly unchanged content of granules at 10 µM is 
probably due to the non-stimulatory glucose concentration (5 mM) during the cell culture 
period.
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While this observation is similar to that made with sulfonylurea-exposed islets (with the 
difference that sulfonylureas induce a stronger degranulation, sometimes even a complete 
emptying of the granule pool, Rustenbeck et al., 2004), the changes in mitochondrial 
morphology appear to be more specific for this group of compounds. Mitochondrial EM changes 
after sulfonylurea exposure showed enhanced content of mitochondria and increased 
mitochondrial volume (Borg and Andersson, 1981). First generation imidazolines, which similar 
to fluoroquinolones block KATP channels by binding to the pore-forming subunit (Grosse-
Lackmann et al., 2003), did not produce such changes. On the other hand, it ought to be 
mentioned that beta cells from KATP of SUR1KO mice contain increased numbers of 
mitochondria, many of which are elongated or otherwise enlarged (Jörns and Rustenbeck, 
unpublished). So it cannot be ruled out that there may be a causal relation between the ability to 
depolarize the beta cell plasma membrane and the induction of changes in mitochondrial 
morphology. On the other hand, the functional changes induced by all three fluoroquinolones in 
SUR1KO islets suggest that the mitochondrial effects are not dependent on the existence of a 
KATP channels in the plasma membrane (see chapter 4.2.3.2). This view concurs with published 
observation of mitochondrial effects of fluoroquinolones in other tissues e.g. skin fibroblasts and 
chondrocytes (Ouédraogo et al., 2000; Stahlmann et al., 2000; Kato, 2008). So the hypothesis
needs to be tested that the changes in beta cell mitochondrial morphology are due to direct effect 
on the mitochondrial metabolism. 
5.3 Correlation of the cytotoxic effects with dysglycemic episodes
Among the currently used fluoroquinolones, gatifloxacin appears to have consumed much of the 
current focus (Frothingham, 2005). Compared to other broad-spectrum oral antibiotics, 
gatifloxacin causes a greater risk of hospitalization for treatment of dysglycemia, and is 
associated with nearly a 17-fold higher risk of hyperglycemia (Park-Wyllie et al., 2006). 
Moreover, it is distinguished from other fluoroquinolones by its exceptional ability to produce 
hypoglycemia and hyperglycemia (Khovidhunkit and Sunthornyothin, 2004; Haerian et al., 
2008).
Several lines of evidence show that the drug concentrations used in the present work correspond 
to values achieved after administrations of therapeutic doses. Regarding gatifloxacin: 
1. A large volume of distribution of gatifloxacin in the pancreas had been shown to play a 
pivotal role in the high occurrence of dysglycemia (Nagai et al., 2010). It is well 
distributed in tissues, often achieving levels that exceed its plasma concentrations 
(Grasela, 2000).
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2. Past investigations on the mechanism of fluoroquinolone-induced dysglycemia usually 
adopted that the blood concentration of gatifloxacin in patients with glycemic 
abnormality episodes has been ???????????????????????????????????????????????????????
while its concentration in pancreatic tissue 1 h after single oral administration was about 
six times higher than blood concentration in rats. The pancreatic gatifloxacin 
?????????????????????????????????????????????????????????????????????g) or levofloxacin 
???? ????), although there was little difference in serum drug concentrations (12 to 15 
?????????????them ( Saraya et al., 2004; Ishiwata et al., 2006a and 2006b; Yamada et al., 
2006; Tomita et al., 2007; Furuhama, 2007).
3. In patients with renal impairments, plasma gatifloxacin levels may double the values 
mostly detected in healthy subjects (Ishiwata et al., 2006b). Moreover, the mean 
elimination half-life of gatifloxacin is relatively long (about 7 h) and urinary excretion of 
unchanged drug is the major route of elimination (Fish and North, 2001).
Similarly, simultaneous measurements of pancreatic tissue and plasma concentrations have 
demonstrated that moxifloxacin readily penetrates into human pancreatic tissue following 
intravenous or oral administration (Wacke et al., 2006). In case of ciprofloxacin, tissue levels 
exceeding the respective serum levels have been reported from human pancreas (Isenmann et al., 
1994).
None of the fluoroquinolones stimulated insulin secretion in the presence of a basal glucose 
concentration (5 mM), but raising the glucose concentration from 5 to 10 mM revealed the 
insulinotropic effect. Thus, the insulinotropic effect of the fluoroquinolones is not an initiation of 
insulin secretion, but rather an enhancement of the stimulatory effect of ? cell nutrients.
We assume that the opposing effects produced by moxifloxacin (on [Ca2+]i and mitochondrial 
de-energization) could explain why this drug is the least to influence glucose homeostasis.
Several approaches using intact or permeabilised cells have shown the involvement of ATP at 
steps of the secretory process distal to the [Ca2+]i increase. So, it is not surprising that increased 
[Ca2+]i ,when associated with a decrease in the energy state of islets/ ? cells, cannot augment 
insulin release (Detimary et al., 1994). 
The results described herein are consistent with clinical experience that among the 
fluoroquinolones, gatifloxacin is associated with the highest risk of hypoglycemia. On the other 
hand, large analyses of pooled data from patients receiving moxifloxacin fail to identify any 
glucose derangement, which could be partially attributed to the pharmacokinetic properties of the 
drug being not renally excreted (Gavin III et al., 2004).
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6. Summary and Perspective
Fluoroquinolones are nowadays an important class of antibacterial agents, possessing a 
broad spectrum of activity against Gram-positive, Gram-negative, and mycobacterial 
organisms, as well as against anaerobes including otherwise resistant strains. In 
particular, treatment of tuberculosis by fluoroquinolones is an area of growing 
importance. Ciprofloxacin and moxifloxacin were shown to exert antineoplastic 
activity in several cancer cell lines. Although they are generally well tolerated, newer 
quinolone derivatives have caused several unexpected adverse reactions including 
severe dysglycemic episodes. Several agents had been withdrawn from the market for 
this reason, such as temafloxacin, clinafloxacin and gatifloxacin. Given the frequency 
with which this group is prescribed and that dysglycemia may be not correlated to the 
intake of these drugs especially in diabetics, cases may be underreported in published 
reports which are strictly conducted in hospitalized patients. The true incidence could 
only be determined through prospective, population-based surveillance. 
Three clinically relevant fluoroquinolones were selected for this study: gatifloxacin, 
ciprofloxacin and moxifloxacin. Gatifloxacin is the fluoroquinolone which is the most 
associated with disturbances of the glucose homeostasis, including several fatalities. Therefore, 
its use is practically discontinued, even though it is a highly effective antibacterial agent. 
Ciprofloxacin can be regarded as the standard fluoroquinolone, there is a number of case reports 
of serious hypoglycemias associated with its use, but the overall risk of dysglycemias is 
generally regarded as acceptable. Moxifloxacin, even though structurally closely similar to 
gatifloxacin, is not associated with serious hypoglycemias.    
Originally, it was believed that fluoroquinolones would only aggravate sulfonylurea-induced 
hypoglycemias, but it is meanwhile clear that co-administration with sulfonylureas is an 
independent risk factor and that fluoroquinolones are inducers of hypoglycemia in their own 
right. In fact, fluoroquinolones increase insulin secretion by inhibiting the activity of the KATP
channels of the pancreatic β cell. However, investigations preceding this thesis work have come 
to the conclusion that the insulinotropic effect is not sufficiently explained solely by the ability 
of the fluoroquinolones to block KATP channels in pancreatic β cells. 
This conclusion was based on a number of observations. In particular, the observation that
fluoroquinolones were able to depolarize open cell preparation of pancreatic beta cells and thus 
to initiate the well-known sequence of opening of voltage-dependent Ca2+ channels and 
triggering the Ca2+ dependent exocytosis, but were unable at an equimolar concentration to do 
the same with metabolically intact β cells (perforated patch configuration) suggested that a 
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metabolism-dependent endogenous factor might counteract the KATP channel-blocking effect of 
the fluoroquinolones. 
Supposing that an interference with mitochondrial energy metabolism was the reason for this 
discrepancy, the effect of gatifloxacin, ciprofloxacin and moxifloxacin on NAD(P)H- and FAD-
autofluorescence, the mitochondrial membrane potential (Rhodamine 123-fluorescence) and 
adenine nucleotide content of isolated pancreatic islets were investigated in this thesis. Initially 
however, the [Ca2+]i concentration was measured to check whether the depolarizing ability (or 
inability) of the fluoroquinolones translated directly into changes of the cytosolic Ca2+
concentration which is regarded as the direct triggering factor of exocytosis. 
In fact, it could be shown that in the presence of a basal glucose concentration (5 mM) all three 
fluoroquinolones were unable to increase [Ca2+]i at 100 µM while at 500 µM a clear increase of
[Ca2+]i could be observed. This concentration dependency concurs with that to depolarize 
metabolically intact β cells. In the presence of 10 mM glucose, which by itself raises [Ca2+]i, a 
clear further increase of [Ca2+]i was produced by all compounds, which was partially 
antagonized by D-600, a blocker of L-type Ca2+ channels and by diazoxide, an opener of KATP
channels. Thus it can be concluded that a depolarization-induced Ca2+ influx plays a role in the 
[Ca2+]i increase, but does not wholly explain it. This hypothesis was confirmed by the 
observation that all three fluoroquinolones at 100 µM produced a moderate but unmistakable 
[Ca2+]i increase in SUR1KO islets, which do not have functional KATP channels. Apparently, 
fluoroquinolones affect [Ca2+]i by one or more mechanisms unrelated to the block of KATP
channels. 
Since the fluoroquinolone fluorescence interfered with the measurement of the NAD(P)H- and 
FAD-autofluorescence of the perifused islets, the exposure to the fluoroquinolones took place 
during a 1 h preincubation period, followed by a perifusion first without glucose and then with 
glucose at a stimulatory concentration. 100 µM of moxifloxacin, but not of ciprofloxacin or 
gatifloxacin abolished the NAD(P)H increase typically elicited by 20 mM glucose. Similarly, 
moxifloxacin and, to a lesser degree, ciprofloxacin diminished the glucose-induced decrease of 
FAD-fluorescence, which is a more specific indicator of the intramitochondrial production of 
reducing equivalents. Moxifloxacin, but not ciprofloxacin or gatifloxacin significantly reduced 
the ATP-to-ADP ratio produced by 20 mM glucose, thereby confirming the inhibitory effect on 
mitochondrial energetics and at least partly explaining the lack of depolarizing effect in intact 
beta cells at basal glucose. However, in the presence of basal glucose (5 mM) a significant 
inhibitory effect on the ATP-to-ADP ratio could not be verified. 
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Initially, the effect of the fluoroquinolones on the mitochondrial membrane potential was 
measured using the same experimental protocol as for the measurement of the NAD(P)H- or 
FAD-fluorescence, i.e. after a preincubation period. Using this protocol, there was no obvious 
reduction of the glucose (20 mM) -induced hyperpolarization. However, when the exposure to 
the fluoroquinolones was done during the measurements, it was found that all three 
fluoroquinolones produced a slowly progressing hyperpolarization of the mitochondrial 
membrane potential. This effect was most marked with moxifloxacin, which even somewhat 
inhibited the depolarizing effect of the uncoupler, CCCP. When the fluoroquinolones were 
added after a stimulatory glucose concentration (20 mM) had established a hyperpolarized 
membrane potential of the mitochondria, an antagonizing effect of moxifloxacin, but not of gati-
or ciprofloxacin became visible. 
From the data obtained during this thesis work it can be concluded that fluoroquinolones affect β
cells functions beyond blocking KATP channels. This is obvious in the case of the [Ca
2+]i
increase in SUR1KO islets. This KATP channel-independent increase in [Ca
2+]i could be 
secondary to the interference of the fluoroquinolones with mitochondrial functions. Obviously, 
fluoroquinolones counteract the effect a stimulatory glucose concentration, but have little or no 
effect in the presence of a basal glucose concentration. Intriguingly, the most marked effect on 
the parameters of mitochondrial energetics is exerted by moxifloxacin. Given the central role of 
β cell energetics in the stimulus-secretion coupling, this effect of moxifloxacin may counteract 
the consequences of the KATP channel block for the release of insulin. This would explain why in 
clinical use this compound is the least associated with hypoglycemias. 
Certainly, this hypothesis requires verification and a further elucidation of the mitochondrial site 
of action of the fluoroquinolones. The autofluorescence of the fluoroquinolones is a considerable 
obstacle in this regard, precluding a number of useful experimental protocols. To pinpoint the 
exact nature of this interference will thus require the measurement of additional parameters such 
as oxygen consumption. Finally, it cannot be excluded that other mechanisms not considered 
here may also affect insulin secretion such as Mg2+ chelation, suppression of GLUT1 function or 
interaction with the neurotransmitter, GABA.  Because there is a growing need for antibacterial 
drugs, e.g. for the treatment of tuberculosis, and because the development of fluoroquinolones is 
ongoing, the knowledge which structural features contribute to the insulinotropic property may 
be decisive for the availability of effective and safe compounds of this class. 
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